Single-Cell Atlas of Kidney Cancer: Unveiling B-cell Malignancy, Microenvironmental Remodeling, and Intercellular Communication
This single-cell analysis reveals a profound shift in kidney tissue from adjacent normal to tumor conditions, characterized by distinct cellular landscapes, genomic instability, and altered cell-cell interactions. B cells, identified as the tumor-origin cell type, exhibit copy number variations consistent with malignancy. The tumor microenvironment is extensively remodeled with significant immune cell infiltration and activation of pro-tumorigenic signaling pathways, alongside metabolic reprogramming in resident kidney cells. These findings highlight key cellular and molecular drivers of kidney cancer progression, offering potential diagnostic and therapeutic avenues.
Contents
- Dataset overview
- UMAP Visualization of Kidney scRNA-seq Data Across Conditions, Cell Types, and Ploidy Status
- Endothelial Cell Condition-Specific Marker Expression in Kidney Tissue
- CNV Heatmap Analysis of B Cells and Unassigned Cells in Kidney Tumor Samples
- CNV-Derived UMAPs Revealing Cell Type, Ploidy, Condition, and Sample Distributions in Kidney Tissue
- Minor Cell Type Population Analysis in Kidney Tissue
- 신장암 미세환경 내 T세포 및 선천 림프구 아형의 조성 변화 분석
- Macrophage Population Consistency at the Minor Cell Type Level
- Differential Proportion of Cytotoxic T Cells in Kidney Tumor Microenvironment
- Differential Macrophage Subtype Proportions in Kidney Tumor Microenvironment
- Ploidy Population Analysis of B Cells (Tumor-Origin) and Unassigned Cells in Kidney Tumor vs. Adjacent Normal Tissue
- Condition-Specific Cell-Cell Interaction Analysis in Kidney Tissue
- Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Kidney Tumor Microenvironment
- Condition-Specific Cell-Cell Interaction Patterns in Kidney Tissue
- B cell Surfaceome Marker Analysis in Kidney Tissue
- Cell-Type Specific Surfaceome Marker Landscape in Kidney Tissues, Focusing on Fibroblasts
- CD4+ T Cell Condition-Specific Surfaceome Markers in Kidney Tissue
- Differential Expression of Cell Cycle Genes in Kidney Collecting Duct Principal Cells
- Cell-Type-Specific Gene Ontology Pathway Enrichment in Kidney Tumor Microenvironment
- Gene Set Enrichment Analysis (GSEA) of Kidney Tumor Microenvironment Cell Types
- Discussion
- Query List
0. Dataset overview
Dataset Summary
- This dataset contains single-cell RNA-seq data from human Kidney tissue.
- It includes 49,645 cells and 19,593 genes.
- Two conditions are present: 'tumor' and 'adjacent_normal'.
- Major cell types include Podocyte, Myeloid cell, Endothelial cell, T cell, Stromal cell, B cell, Mast cell, Collecting Duct Principal cell, Distal Tubule, Proximal Tubule, and unassigned cells.
- Minor and subset level cell types provide more granular classification.
- Ploidy information ('Aneuploid', 'Diploid') is available for cells.
- Precomputed analysis results include Cell-Cell Interaction (CCI), Differential Gene Expression (DEG), Gene Set Enrichment Analysis (GSEA), and Gene Ontology (GO/GSA) for various cell types and conditions.
- CNV estimates are available, and the tumor origin cell type is identified as B cell.
1. UMAP Visualization of Kidney scRNA-seq Data Across Conditions, Cell Types, and Ploidy Status
[Analysis Visualization Results]...
Analysis Overview
This analysis provides UMAP (Uniform Manifold Approximation and Projection) visualizations of single-cell RNA sequencing data from kidney tissue. UMAP is a dimensionality reduction technique used to visualize high-dimensional data, such as gene expression, in a lower-dimensional space (here, 2D) while preserving the global and local structure of the data. These plots illustrate the distribution of cells colored by various metadata attributes: condition (tumor vs. adjacent_normal), sample (individual patient samples), celltype_major, celltype_minor, celltype_subset (hierarchical cell type annotations), and ploidy_dec (ploidy inference label). The primary goal is to assess cell population structure, the relationship between different biological variables, and the quality of cell annotations within the embedding space.
Visual Summary
Condition
The UMAP colored by condition shows a clear segregation of cells into two major compartments. Cells from "tumor" (blue) are predominantly located in the upper-right region and some central clusters, while cells from "adjacent_normal" (red) are enriched in the lower-left region and other peripheral clusters. This indicates significant transcriptomic differences between tumor and adjacent normal tissues, leading to distinct cellular landscapes in the reduced dimension space.
Sample
The sample UMAP reveals that individual samples (N1-N9 for normal, T1-T9 for tumor) exhibit some degree of clustering. Normal samples (N1-N9, various shades of yellow/orange) largely correspond to the "adjacent_normal" regions identified in the condition plot, while tumor samples (T1-T9, various shades of green/blue/purple) largely correspond to the "tumor" regions. While some mixing occurs, the overall pattern suggests that patient-specific differences or batch effects exist, though the primary separation appears to be driven by the disease condition.
Celltype_major, Celltype_minor, and Celltype_subset
These three UMAPs provide progressively finer granularity of cell type annotations.
- Celltype_major: Distinct clusters generally correspond well to the broad cell categories. For instance, "Proximal Tubule" (light green) and "Distal Tubule" (orange) form large, well-defined clusters, reflecting the epithelial structures of the kidney. "Myeloid cell" (yellow) and "T cell" (dark blue) also form distinguishable clusters, indicating the presence of immune cell populations. An "unassigned" cluster (dark blue) is present, suggesting cells that could not be confidently classified into a major cell type.
- Celltype_minor: This level further refines the annotations, resolving major types into sub-populations (e.g., "Macrophage" from Myeloid cell, "T cell CD4+" and "T cell CD8+" from T cell). The overall clustering structure remains consistent, with these minor cell types forming coherent sub-clusters within their major type regions. Kidney-specific cell types like "Podocyte" (light green) and "Collecting Duct Principal cell" (red) are also distinctly visible.
- Celltype_subset: At the most granular level, celltype_subset reveals fine-grained populations like "Macrophage (M1)", "T cell (Cytotoxic)", and specific segments of the kidney tubules (e.g., "Proximal Convoluted Tubule S1_S2"). These annotations largely respect the underlying UMAP structure, demonstrating good concordance between transcriptional profiles and highly resolved cell identities. The "unassigned" category also persists at this level.
Ploidy_dec
The UMAP colored by ploidy_dec shows cells labeled as "Diploid" (red) distributed across the entire embedding, including both adjacent normal and tumor regions. Cells labeled "Unclear" (purple) are also broadly distributed but appear notably enriched in certain regions, particularly within the clusters that are predominantly "tumor" cells. It is important to note the data context mentions ploidy_dec: Aneuploid, Diploid, while the plot legend shows "Diploid" and "Unclear". This suggests that "Unclear" may represent cells with indeterminate ploidy status, potentially including cells that could not be confidently classified as diploid or aneuploid based on the CNV estimates (obsm['X_cnv']), or could encompass cells that are indeed aneuploid but were labeled "Unclear" in this specific visualization.
Biological Interpretation
The UMAP visualizations provide crucial insights into the cellular landscape of kidney tissue in the context of cancer.
- Disease-Associated Transcriptomic Shifts: The striking separation of "tumor" and "adjacent_normal" cells underscores the profound changes in gene expression profiles occurring in kidney cancer. This clear partitioning validates the utility of single-cell RNA-seq in distinguishing diseased from healthy tissue components at the cellular level. This segregation forms a robust foundation for subsequent differential gene expression and pathway analyses.
- Diverse Kidney Cellular Ecosystem: The comprehensive cell type annotations, spanning major categories to fine-grained subsets, highlight the remarkable cellular heterogeneity of the human kidney. The presence of various epithelial cells (proximal tubules, distal tubules, collecting duct, podocytes), immune cells (T cells, B cells, macrophages, NK cells, ILCs), and stromal cells (fibroblasts, smooth muscle cells, endothelial cells) paints a detailed picture of the kidney's complex microenvironment. The consistency of these annotations with the UMAP clusters suggests high quality and robust identification of cell populations.
- Immune Cell Infiltration and Heterogeneity: The identification of numerous immune cell subtypes (e.g., Macrophage M1/M2 subsets, T cell CD4+/CD8+/Treg/Th1/Th2, B cell Follicular/Breg) reflects the dynamic immune responses and inflammation often associated with cancer. The distinct clustering of these populations suggests diverse functional states within the tumor microenvironment and adjacent normal tissue.
- Ploidy Status and Tumor Biology: The observation that "Unclear" ploidy cells are enriched in tumor-specific regions is biologically significant. Given that aneuploidy (abnormal chromosome number) is a hallmark of cancer and is often inferred from CNV profiles, it is highly probable that a substantial fraction of these "Unclear" cells within the tumor clusters are indeed aneuploid or display genomic instability. The presence of "Diploid" cells within tumor regions indicates a mixed tumor cellularity, including potentially non-transformed stromal or immune cells, or tumor cells that retain a diploid state. Further investigation into the "Unclear" category, potentially re-evaluating with more stringent aneuploidy calling, would be beneficial.
Annotation Notes
The hierarchical cell type annotations (major, minor, subset) show excellent concordance with the UMAP embedding, indicating robust cell identity assignment. The persistence of an "unassigned" category across all cell type granularities suggests that a small population of cells either lacks strong markers for current annotations or represents novel/rare cell types that warrant further exploration. The discrepancy between the ploidy_dec data context (Aneuploid, Diploid) and the plot legend (Diploid, Unclear) should be noted, as "Unclear" cells, particularly those enriched in tumor regions, might represent cells with abnormal ploidy that were not confidently labeled as "Aneuploid" in the plot due to visualization choices or ambiguous CNV signals.
2. Endothelial Cell Condition-Specific Marker Expression in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This dot plot visualizes marker gene expression within Endothelial cells, comparing 'adjacent_normal' kidney tissue samples to 'tumor' kidney tissue samples. Each row represents a specific sample (N for normal, T for tumor), and each column represents a gene. The size of the dot corresponds to the fraction of cells within that sample expressing the gene, while the color intensity reflects the mean expression level of the gene in those cells. The analysis aims to identify genes that are specifically upregulated or downregulated in endothelial cells based on the tissue condition, thereby highlighting condition-specific endothelial phenotypes.
Visual Summary
The dot plot reveals a striking and clear separation of marker gene expression profiles between endothelial cells derived from 'adjacent_normal' and 'tumor' kidney samples:
- Adjacent Normal Endothelial Markers: A distinct cluster of genes (highlighted in the top-left red box) shows high expression and prevalence exclusively in endothelial cells from 'adjacent_normal' samples (N1-N9). Key genes in this group include MTRNR2L12, IGFBP5, MT2A, MTRNR2L8, MT1E, ALDOB, DNASE1L3, PLAT, CRHBP, GPX3, PLVAP, and MT1G. These genes are largely absent or expressed at very low levels in tumor-derived endothelial cells.
- Tumor Endothelial Markers: Conversely, a separate and robust set of genes (highlighted in the bottom-right red box) is strongly expressed and widely prevalent in endothelial cells from 'tumor' samples (T2-T9). This group includes genes such as SPARCL1, RGCC, SPRY1, VWF, HSPG2, CCDC85B, INSR, COL4A1, TCF4, COL4A2, ESM1, VWA1, CLEC14A, ADGRL4, APLP2, PRSS23, ANGPT2, CAV1, EDNRB, APOLD1, IGFBP3, MGLL, NFIB, HTRA1, CXorf36, CYTOR, LAMA4, STC1, and MCAM. These tumor-associated markers show minimal to no expression in adjacent normal endothelial cells.
- Consistency within Conditions: Within each condition, the expression patterns for these respective marker sets appear largely consistent across different individual samples, indicating a robust condition-dependent endothelial phenotype.
- Cell Counts: The bar chart on the right indicates varying numbers of endothelial cells per sample, ranging from 56 (N5) to 1280 (T2), yet this variability does not disrupt the clear segregation of marker patterns.
Biological Interpretation
The observed differential gene expression profoundly reflects the distinct biological states of endothelial cells in normal kidney tissue versus the tumor microenvironment.
- Endothelial Cells in Adjacent Normal Kidney: The markers enriched in normal endothelial cells likely represent genes involved in maintaining quiescent vascular homeostasis and specific kidney endothelial functions.
- MTRNR2L12, MT2A, MT1E, MT1G (metallothioneins) are known for their roles in metal ion detoxification and protection against oxidative stress, suggesting a baseline protective mechanism in normal vessels.
- IGFBP5 (Insulin-like growth factor-binding protein 5) regulates IGF signaling, important for normal tissue maintenance and repair.
- PLAT (Plasminogen activator, tissue type) is critical for fibrinolysis and extracellular matrix remodeling, essential for healthy vascular physiology.
- PLVAP (Plasmalemma vesicle associated protein) is characteristic of fenestrated endothelium, which is abundant in specific kidney capillaries like the glomeruli, suggesting specialized endothelial function.
- Endothelial Cells in Kidney Tumors: The highly expressed genes in tumor-associated endothelial cells signify an activated, pro-angiogenic, and tumor-supportive phenotype, crucial for tumor growth and metastasis.
- Genes like SPARCL1, RGCC, SPRY1, HSPG2 (perlecan), COL4A1/A2 (collagen type IV) are associated with cell proliferation, extracellular matrix remodeling, and basement membrane components, all integral to pathological angiogenesis and tumor invasion.
- VWF (von Willebrand Factor) is a fundamental endothelial marker; its robust expression confirms the cell type while also potentially indicating altered hemostatic or angiogenic activity in the tumor context.
- ESM1 (Endothelial cell-specific molecule 1, endocan) is a soluble proteoglycan that promotes angiogenesis and is often highly expressed in tumor endothelium, acting as a pro-angiogenic factor UniProt: P60604.
- Several genes are established players in angiogenesis and vascular remodeling: CLEC14A (C-type lectin domain family 14 member A), ADGRL4 (Adhesion G protein-coupled receptor L4, ELTD1), ANGPT2 (Angiopoietin 2), CAV1 (Caveolin 1), and EDNRB (Endothelin receptor type B). ANGPT2 is particularly notable for promoting vascular destabilization and sprouting angiogenesis, which is critical for tumor neovascularization PubMed Search: ANGPT2 tumor angiogenesis.
- MCAM (Melanoma cell adhesion molecule, CD146) is a cell adhesion molecule involved in endothelial cell migration, proliferation, and organization into new vessels, and is frequently upregulated in tumor vasculature GeneCards: MCAM.
Clinical or Translational Implications
The distinct sets of condition-specific markers identified in Endothelial cells hold significant clinical and translational potential.
- Biomarker Identification: The tumor-specific endothelial markers (e.g., ESM1, ANGPT2, MCAM, CLEC14A) could serve as valuable diagnostic or prognostic biomarkers for kidney cancer. Detecting their expression patterns, perhaps through immunohistochemistry or circulating endothelial cells, could help distinguish tumor tissue from benign lesions, assess tumor aggressiveness, or monitor treatment efficacy.
- Therapeutic Targets: The genes highly expressed in tumor endothelial cells, especially those directly involved in angiogenesis and tumor support, represent promising therapeutic targets.
- Inhibiting the activity of pro-angiogenic factors like ANGPT2 or ESM1 could suppress the formation of new blood vessels crucial for tumor growth, thereby "starving" the tumor. Therapies targeting ANGPT2 are actively being investigated in oncology PubMed Search: ANGPT2 inhibitors cancer therapy.
- Targeting cell surface proteins like MCAM or CLEC14A on tumor endothelium could allow for antibody-drug conjugates or other targeted delivery systems to specifically deliver cytotoxic agents to tumor vasculature, minimizing off-target effects on normal tissues.
- Experimental Validation: Further experimental validation is warranted to confirm the functional significance of these markers.
- *In vitro* studies could involve gene knockdown/overexpression in endothelial cell lines to assess impacts on proliferation, migration, tube formation, and interaction with renal tumor cells.
- *In vivo* experiments using orthotopic kidney cancer models could evaluate the therapeutic efficacy of targeting these markers, assessing effects on tumor growth, metastasis, and vascular integrity.
- Analysis of human kidney tumor biopsies using multiplex immunofluorescence or spatial transcriptomics would be crucial to confirm the protein expression and spatial localization of these markers within the tumor microenvironment.
3. CNV Heatmap Analysis of B Cells and Unassigned Cells in Kidney Tumor Samples
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates copy number variation (CNV) patterns in B cells (identified as tumor-origin cells) and unassigned cells from kidney tumor samples T5, T7, and T9 using single-cell RNA sequencing data. The heatmap visualizes the log2(Copy Number Ratio, CNR) for individual cells (rows) across genomic spots (columns), allowing for the identification of recurrent amplifications (red) and deletions (blue) within and across samples. This provides insight into the genomic instability characteristic of these cell populations and potential clonal relationships.
Visual Summary
The heatmap displays the log2(CNR) values, where positive values (red) indicate copy number amplifications and negative values (blue) indicate copy number deletions. The cells are grouped by sample (T5, T7, T9) on the y-axis, and genomic spots are ordered by chromosome along the x-axis.
Overall Patterns:
- Across all three samples (T5, T7, T9), distinct and recurrent CNV patterns are observable, suggesting clonal genomic alterations within these B cell/unassigned populations.
- There is a clear mosaic pattern of amplifications and deletions, with some regions showing consistent changes across many cells within a sample.
Sample-Specific Observations:
Sample T5:
- Shows clear amplifications on chromosome 1 (proximal region), chromosome 2 (distal region), chromosome 3 (mid-region), chromosome 7 (mid-to-distal region), chromosome 8 (mid-to-distal region), chromosome 11 (mid-region), chromosome 16 (proximal-to-mid region), and chromosome 17 (proximal region).
- Notable deletions are observed on chromosome 6 (mid-region), chromosome 13 (proximal-to-mid region), chromosome 14 (proximal-to-mid region), and chromosome 18 (mid-region). The deletions on chr13 and chr14 appear relatively broad and consistent.
Sample T7:
- Exhibits robust amplifications on chromosome 1 (proximal region), chromosome 2 (distal region), chromosome 3 (mid-region), chromosome 7 (mid-to-distal region), chromosome 8 (mid-to-distal region), chromosome 11 (mid-region), chromosome 16 (proximal-to-mid region), and chromosome 17 (proximal region).
- A prominent and consistent deletion is evident on chromosome 6 (mid-region). Other deletions are seen on chromosome 13 (proximal-to-mid region), chromosome 14 (proximal-to-mid region), and chromosome 18 (mid-region). The chr6 deletion appears particularly strong and widespread within this sample.
Sample T9:
- Displays clear amplifications on chromosome 1 (proximal region), chromosome 2 (distal region), chromosome 3 (mid-region), chromosome 7 (mid-to-distal region), chromosome 8 (mid-to-distal region), chromosome 11 (mid-region), chromosome 16 (proximal-to-mid region), and chromosome 17 (proximal region).
- Similar to T7, a distinct and strong deletion is observed on chromosome 6 (mid-region). Other deletions are present on chromosome 13 (proximal-to-mid region), chromosome 14 (proximal-to-mid region), and chromosome 18 (mid-region). The amplifications on chr3, chr7, chr8, and chr16, along with the deletion on chr6, are highly consistent across cells in T9.
Summary of Significantly Amplified and Deleted Regions:
Consistent Amplifications across Samples (T5, T7, T9):
Chromosome 1 (proximal)
Chromosome 2 (distal)
Chromosome 3 (mid-region)
Chromosome 7 (mid-to-distal)
Chromosome 8 (mid-to-distal)
Chromosome 11 (mid-region)
Chromosome 16 (proximal-to-mid)
Chromosome 17 (proximal)
Consistent Deletions across Samples (T5, T7, T9):
Chromosome 6 (mid-region – particularly strong in T7 and T9)
Chromosome 13 (proximal-to-mid)
Chromosome 14 (proximal-to-mid)
Chromosome 18 (mid-region)
Biological Interpretation
The observed recurrent and widespread CNVs in B cells across the kidney tumor samples T5, T7, and T9 strongly support their classification as tumor-origin cells, as indicated in the data context. The presence of these consistent genomic alterations is a hallmark of cancer cells, which accumulate somatic mutations, including CNVs, during malignant transformation and clonal expansion PMID: 23143598.
- Clonal Evolution and Tumor Heterogeneity: The consistent patterns of amplifications and deletions within each sample suggest a clonal origin and subsequent evolution of these B cells. While there are common CNV regions across samples, the subtle differences in specific regions or magnitudes of CNVs among T5, T7, and T9 could reflect inter-patient variability or divergent clonal evolution paths within the tumor microenvironment.
- Aneuploidy: Cells exhibiting extensive CNVs, as seen in the heatmap, would likely be classified as 'Aneuploid' in the ploidy_dec column of the obs data, consistent with the genomic instability. This provides a clear link between the visual CNV data and the inferred ploidy status.
- Role of B cells in Kidney Tumors: The identification of B cells as tumor-origin in kidney tissue is an interesting finding. While B-cell lymphomas can occur in the kidney PMID: 29778235, the primary context here is kidney tissue, which could imply a B-cell specific neoplasm within the kidney or metastatic disease. The observed CNVs provide genomic evidence supporting their neoplastic nature.
- Unassigned Cells: If the "unassigned" cells also exhibit similar CNV patterns to the B cells within the same sample, it would suggest that these cells are likely also part of the neoplastic clone and might represent either misclassified B cells or a closely related subpopulation that has undergone similar genomic changes. This could serve as a valuable internal validation for cell type annotation or an indicator of cellular plasticity.
Clinical or Translational Implications
- Biomarkers for Diagnosis and Prognosis: The recurrent CNVs identified could potentially serve as genomic biomarkers for the diagnosis and prognosis of B-cell related kidney tumors. Specific amplifications or deletions might correlate with disease aggressiveness or response to therapy.
- Targeted Therapies: Regions of consistent gene amplification often harbor oncogenes. Further investigation into specific genes located within these amplified regions (e.g., chr8q, chr17p) could identify potential therapeutic targets. Similarly, deletions might pinpoint tumor suppressor genes.
- Understanding Tumor Biology: Characterizing the CNV landscape provides critical insights into the underlying genomic alterations driving B-cell neoplasia in the kidney. This understanding can contribute to a more precise classification of these tumors and better-informed treatment strategies.
4. CNV-Derived UMAPs Revealing Cell Type, Ploidy, Condition, and Sample Distributions in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes single-cell RNA-seq data from kidney tissue on a Uniform Manifold Approximation and Projection (UMAP) embedding. Crucially, this UMAP was constructed using Copy Number Variation (CNV) estimates (cnv=True), meaning the spatial relationships between cells on the UMAP directly reflect their similarity in CNV profiles. The UMAPs are colored by major cell type, minor cell type, inferred ploidy status, experimental condition (tumor vs. adjacent normal), and individual sample, providing a comprehensive overview of how these characteristics relate to genomic alterations.
Visual Summary
The UMAP plots display the distribution of 49,645 cells based on their CNV patterns.
Cell Type (Major and Minor):
- Both celltype_major and celltype_minor plots show distinct clustering of different cell types, suggesting that specific cell types, or groups of cell types, exhibit characteristic CNV profiles. For example, Podocytes (light green), Proximal Tubule cells (dark green), and Distal Tubule cells (orange) occupy different regions of the UMAP, indicating potentially distinct basal CNV patterns or susceptibility to CNV.
- Immune cells like T cells (light blue), B cells (dark red), and Myeloid cells (light yellow) also form distinct clusters, suggesting their CNV profiles differ from epithelial or stromal cells.
- The unassigned cells are distributed across multiple regions, highlighting the challenges in assigning definitive cell types based on current markers or the presence of transitional states.
Ploidy Status (ploidy_dec):
- The UMAP colored by ploidy_dec reveals a clear separation between cells labeled "Diploid" (dark red) and "Unclear" (purple).
- The majority of cells on the left side of the UMAP are "Diploid," while a substantial population on the right side and top-right are labeled "Unclear." Given the ploidy_dec column in context can contain "Aneuploid," it is highly probable that "Unclear" in this visualization represents cells with inferred aneuploidy or significant CNV, where a clear diploid state is not evident. This strong segregation indicates that CNV estimates effectively distinguish between different ploidy states.
Condition:
- The condition plot shows a striking segregation. Cells from "adjacent_normal" tissue (dark red) largely overlap with the "Diploid" region observed in the ploidy_dec plot, predominantly on the left side of the UMAP.
- Conversely, cells from "tumor" tissue (purple) predominantly occupy the "Unclear" region on the right and top-right of the UMAP. This strong correlation suggests that tumor cells are characterized by significant CNVs or aneuploidy, which is effectively captured by the CNV-derived UMAP.
Sample:
- The sample plot reveals that cells from different samples (N1-N9, T2-T9) are not uniformly mixed across the UMAP.
- "N" samples (adjacent normal, various shades of red/orange/yellow) generally cluster with the "Diploid" and "adjacent_normal" regions on the left.
- "T" samples (tumor, various shades of green/blue/purple) tend to cluster with the "Unclear" and "tumor" regions on the right.
- While there is a clear separation between normal and tumor samples, some individual samples show broader distributions or overlap, indicating heterogeneity within tumor samples and potentially varied CNV profiles across patients. This also suggests that batch effects due to sample processing are not overwhelming the biological signal of CNV and condition.
Biological Interpretation
The UMAP embedding, explicitly leveraging CNV estimates, provides a powerful visualization of genomic instability across cell types and conditions in kidney tissue.
- Tumor-Specific Aneuploidy/CNV: The strong segregation of "tumor" cells to the "Unclear" ploidy region is a key finding. This indicates that kidney tumor cells in this dataset exhibit widespread chromosomal abnormalities (aneuploidy or other significant CNVs), which is a hallmark of many cancers PMID: 28981643. This molecular feature effectively distinguishes tumor cells from adjacent normal cells.
- Cell Type-Specific CNV Signatures: The distinct clustering of various cell types on the CNV UMAP suggests that even within normal tissue, different cell types may have subtle yet distinct baseline CNV profiles, or that certain cell types are more prone to specific CNV alterations during tumorigenesis. For example, the separation of Podocytes and Tubule cells implies unique genomic landscapes for these specialized kidney cell populations.
- Tumor Microenvironment Complexity: The presence of various non-epithelial cell types (Myeloid, T, B, Stromal cells) within the tumor region (overlapping with "Unclear" ploidy) indicates their infiltration into the tumor microenvironment. While these immune and stromal cells might retain a diploid state (which is not directly visible for individual immune cells within the larger "Unclear" blob, but generally expected for non-transformed cells), their clustering alongside aneuploid tumor cells on a CNV-derived UMAP might reflect either their spatial proximity and influence by the tumor, or potentially, subtle CNV changes in stromal components. Further investigation into the ploidy status of specific immune and stromal cell types within the tumor environment would be informative.
- Sample Heterogeneity: The distribution of individual samples highlights patient-to-patient variability in CNV patterns. While a general tumor vs. normal separation exists, the differing spatial extents and overlaps of individual "T" samples suggest inter-patient heterogeneity in the specific genomic alterations driving kidney tumorigenesis. Similarly, the "N" samples, while largely diploid, show some variability that might reflect individual genomic backgrounds or subtle age-related CNVs.
Annotation Notes
- The ploidy_dec plot, labeling cells as "Diploid" or "Unclear," effectively discriminates cell populations based on their inferred genomic stability. For future clarity, explicitly labeling "Unclear" as "Aneuploid" or "CNV-positive" if the underlying inference supports it would enhance interpretation, given the ploidy_dec obs column is described to contain "Aneuploid" and "Diploid."
- The overall quality of cell type annotations appears robust as they form distinct clusters on the CNV-UMAP, suggesting that the identified cell types correspond to distinct biological entities with potentially different genomic characteristics.
- The clear separation of conditions and ploidy status, aligned with expectations for cancer studies, validates the utility of CNV estimation for dissecting tumor heterogeneity in single-cell data.
5. Minor Cell Type Population Analysis in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a stacked bar plot showing the proportional representation of different minor cell types across individual samples from human kidney tissue, categorized into 'adjacent_normal' and 'tumor' conditions. The plot allows for a visual comparison of cell type composition and heterogeneity between healthy kidney tissue adjacent to a tumor and the tumor microenvironment itself.
Visual Summary
The visualization reveals a stark contrast in cell type composition between adjacent normal kidney tissue and tumor samples.
- Adjacent Normal Samples: These samples are predominantly composed of kidney-specific epithelial cell types, including Podocytes, Proximal Tubule cells, Distal Tubule cells, and Collecting Duct Principal cells, which collectively often account for more than 50-60% of the total cells. Endothelial cells and Fibroblasts are also consistently present, along with a minor but variable presence of various immune cells such as Macrophages, T cells (CD4+ and CD8+), B cells, Plasma cells, NK cells, ILCs, and Mast cells.
- Tumor Samples: A dramatic shift in cell proportions is evident in tumor samples:
- Significant Loss of Kidney-Specific Epithelium: Podocytes, Proximal Tubule cells, Distal Tubule cells, and Collecting Duct Principal cells are profoundly reduced or almost entirely absent in most tumor samples, indicating extensive disruption of normal kidney architecture.
- Dominant Immune Cell Infiltration: There is a pronounced increase in immune cell populations, particularly T cells. Both CD4+ T cells and CD8+ T cells show a substantial expansion, often dominating the cellular landscape in tumor samples (e.g., T8, T2, T9, T5, T7). Macrophages also appear to be relatively more abundant in several tumor samples (e.g., T4, T8, T9, T6). Other immune cells like B cells, Plasma cells, NK cells, ILCs, and Mast cells are also present and contribute to the tumor microenvironment.
- Stromal Presence: Fibroblasts and Endothelial cells maintain a noticeable, and in some cases, a relatively increased presence within the tumor microenvironment.
- Heterogeneity: While the general trends are clear, there is some sample-to-sample variability within both 'adjacent_normal' and 'tumor' groups, especially in the precise proportions of immune cell subsets.
Biological Interpretation
The observed cellular landscape reflects fundamental biological processes occurring during renal tumorigenesis and progression.
- Loss of Kidney Parenchymal Identity: The near-absence of specialized renal epithelial cells (Podocytes, Proximal Tubule, Distal Tubule, Collecting Duct Principal cells) in tumor samples signifies the destruction or dedifferentiation of functional kidney tissue. This is a hallmark of renal cell carcinoma, where malignant epithelial cells proliferate and replace normal structures.
- Remodeling of the Tumor Microenvironment (TME): The significant increase in immune and stromal cells indicates a profound remodeling of the tissue microenvironment in the tumor.
- Immune Infiltration: The prominent infiltration of T cells (CD4+ and CD8+) suggests an active immune response within the kidney tumor microenvironment [PubMed Search]. CD8+ T cells are typically cytotoxic and critical for anti-tumor immunity, while CD4+ T cells play diverse roles, including helper and regulatory functions. The presence of Macrophages is also characteristic, as tumor-associated macrophages (TAMs) can promote tumor growth, angiogenesis, and immunosuppression, often adopting an M2-like phenotype [UniProt]. The presence of B cells, Plasma cells, and NK cells further highlights a complex immune landscape.
- Stromal Contributions: The consistent presence of Fibroblasts indicates the likely formation of cancer-associated fibroblasts (CAFs), which are known to contribute to extracellular matrix remodeling, angiogenesis, and immunosuppression, thereby supporting tumor growth and metastasis [PubMed Search]. Endothelial cells are crucial for angiogenesis, providing nutrients and oxygen to the rapidly growing tumor.
- Disease-Specific Cell-State Shifts: The shift from a highly epithelial-dominated structure in normal tissue to an immune and stromal-rich environment in tumors is a classic signature of many solid malignancies, including renal cancers. This highlights the dynamic interplay between tumor cells, immune cells, and stromal components that dictate tumor behavior.
Clinical or Translational Implications
The findings from this cell type population analysis carry several important clinical and translational implications for kidney cancer:
- Immunotherapeutic Potential: The robust infiltration of T cells, particularly CD8+ T cells, suggests that these kidney tumors may be responsive to immunotherapeutic strategies, such as immune checkpoint blockade (e.g., PD-1/PD-L1 inhibitors) [PubMed Search]. Further investigation into the activation state and functional phenotypes of these T cells and macrophages could inform patient stratification and therapeutic selection.
- Diagnostic and Prognostic Biomarkers: The drastic changes in cell composition, especially the loss of specific renal epithelial cells and the concurrent increase in immune and stromal components, could serve as novel diagnostic markers or aid in distinguishing tumor from normal tissue. Specific immune cell ratios or densities might also hold prognostic value for disease progression or response to treatment.
- Understanding Kidney Dysfunction: The extensive loss of functional kidney cell types (Podocytes, tubule cells) in the tumor region implies potential impairment of overall kidney function in patients with renal cancer, which is a common clinical concern. This compositional analysis reinforces the need to monitor renal health in these patients.
6. 신장암 미세환경 내 T세포 및 선천 림프구 아형의 조성 변화 분석
[Analysis Visualization Results]...
Analysis Overview
이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 활용하여 신장 조직의 T 세포 주요 유형(T cell major cell type) 내에서 세포 아형(minor cell types)의 상대적 비율을 비교합니다. 특히, 인접 정상(adjacent_normal) 조직과 종양(tumor) 조직 간의 ILC, NK cell, T cell CD4+, T cell CD8+, 그리고 unassigned 세포의 분포를 개별 샘플 수준에서 시각화하여 미세환경 변화를 파악합니다.
Visual Summary
제공된 막대 그래프는 인접 정상 조직(좌측 패널)과 종양 조직(우측 패널)에서 T 세포 구획 내의 아형별 구성 비율을 보여줍니다. 각 막대는 개별 샘플(N1-N9 for normal, T2-T9 for tumor)을 나타내며, 각 아형은 색상으로 구분됩니다 (ILC: 버건디, NK cell: 주황색, T cell CD4+: 연노랑, T cell CD8+: 노랑, unassigned: 청록색).
- 인접 정상 조직 (adjacent_normal): ILC와 NK 세포가 T 세포 구획 내에서 상당한 비율을 차지하며, 특히 N7, N6, N9, N4 샘플에서 그 비율이 두드러집니다. CD8+ T 세포는 꾸준히 높은 비율을 보이며, CD4+ T 세포도 일정 수준 존재합니다. 샘플 간의 조성에는 다소 이질성이 관찰됩니다.
- 종양 조직 (tumor): 인접 정상 조직과 비교하여 ILC와 NK 세포의 비율이 전반적으로 현저히 감소합니다. 일부 샘플(T6, T2, T5)에서 ILC/NK 세포가 관찰되지만 그 비율은 낮습니다. 반면, CD8+ T 세포의 비율이 매우 높게 유지되거나 더욱 우세해지는 경향을 보이며, 대다수 종양 샘플에서 T 세포 구획의 상당 부분을 차지합니다. CD4+ T 세포는 여전히 존재하지만, CD8+ T 세포만큼 우세하지는 않습니다. unassigned 세포는 두 조건 모두에서 매우 적은 비율을 보입니다.
Biological Interpretation
이러한 T 세포 아형 조성의 변화는 신장암 미세환경에서 면역 반응이 재편되고 있음을 시사합니다.
- CD8+ T 세포의 우세: 종양 조직에서 CD8+ T 세포의 높은 비율은 강력한 항종양 면역 반응의 존재를 나타낼 수 있습니다. CD8+ T 세포는 암세포를 직접적으로 사멸시키는 세포독성 T 림프구(Cytotoxic T Lymphocytes, CTLs)이며, 종양 내 침윤(infiltration)은 일반적으로 더 나은 예후와 연관됩니다. PubMed search: CD8 T cells in kidney cancer prognosis
- NK 세포 및 ILC의 감소: 종양 조직에서 NK 세포와 ILC의 현저한 감소는 주목할 만합니다.
- NK 세포는 선천 면역계의 중요한 구성원으로, 암세포를 인식하고 사멸시킬 수 있는 능력이 있습니다. 종양 내 NK 세포의 감소는 암세포가 NK 세포의 활성을 억제하거나 TME로의 이동을 방해하는 면역 회피 전략을 사용하고 있음을 시사할 수 있습니다. PubMed search: NK cell suppression in tumor microenvironment
- ILC (Innate Lymphoid Cells)는 다양한 기능을 수행하며, 일부 ILC 아형(예: ILC1)은 항종양 활성을 가질 수 있습니다. ILC의 전반적인 감소는 종양 미세환경이 선천 림프구 반응을 억제하는 방향으로 변화하고 있음을 나타낼 수 있습니다. PubMed search: ILCs in cancer immunity
- 이러한 패턴은 신장암 TME가 CD8+ T 세포 반응에 집중되어 있으나, 선천 면역계의 핵심 세포인 NK 세포와 ILC의 기여는 상대적으로 감소하는, 특이적인 면역 조성을 나타냄을 보여줍니다. 이는 암세포가 선천 면역 감시를 회피하는 메커니즘을 발전시켰을 가능성을 시사합니다.
Clinical or Translational Implications
- 면역치료 전략: 신장암에서 CD8+ T 세포의 높은 침윤은 면역 체크포인트 억제제(immune checkpoint inhibitors)와 같은 T 세포 기반 면역치료의 잠재적 반응성을 시사합니다. 하지만 NK 세포와 ILC의 감소는 이러한 치료 반응을 저해할 수 있는 다른 면역 억제 경로가 존재할 가능성을 제시합니다.
- 예후 및 바이오마커: NK 세포 및 ILC 감소와 함께 CD8+ T 세포가 우세한 패턴은 신장암의 예후 인자 또는 면역치료 반응 예측 바이오마커로 추가 연구될 수 있습니다.
- 복합 면역치료 개발: NK 세포 및 ILC의 TME 내 기능을 회복시키거나 증강시키는 전략(예: IL-15와 같은 사이토카인 요법)을 CD8+ T 세포 기반 치료와 병용하는 복합 면역치료 접근법의 가능성을 탐색할 수 있습니다. 이는 선천 면역과 적응 면역 반응을 모두 활성화하여 치료 효과를 극대화하는 데 기여할 수 있습니다. PubMed search: NK cell therapy in cancer
7. Macrophage Population Consistency at the Minor Cell Type Level
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to visualize the population distribution of Macrophages. The plot_celltype_population tool was used, specifically targeting the 'Macrophage' cell type within the celltype_minor taxonomic level. The visualization displays this information across individual samples derived from both adjacent normal and tumor kidney tissues.
Visual Summary
The bar plot presents the cellular composition for the 'Macrophage' celltype_minor category across individual samples, segregated by 'adjacent_normal' and 'tumor' conditions.
- Uniform Composition: For every analyzed sample (N1, N4-N9 representing adjacent normal tissue; T2-T9 representing tumor tissue), the bar corresponding to 'Macrophage' reaches 100% of the Y-axis.
- Consistent Labeling: This indicates that within the set of cells already classified under the 'Macrophage' celltype_minor category, no further distinct sub-classifications at the celltype_minor level were identified or displayed.
- Lack of Sub-type Resolution: As presented, the plot does not illustrate the distribution or proportions of more granular macrophage subsets (e.g., M1, M2 macrophages) which are typically found within the broader macrophage population.
Biological Interpretation
This visualization primarily serves as a confirmation of the consistent annotation and identification of cells belonging to the 'Macrophage' celltype_minor group across all included samples and experimental conditions.
- Annotation Consistency: The uniform 100% representation of 'Macrophage' for each sample confirms the robust and consistent classification of this cell population at the minor cell type level throughout the dataset. This ensures that all cells designated as 'Macrophage' at this taxonomic level are indeed accounted for under that single label.
- Limited Sub-population Insights: It is important to note that this plot does not provide insight into the relative abundance of macrophages when compared to other major or minor cell types within the overall tissue microenvironment. More critically, it does not delineate the presence or proportions of diverse macrophage polarization states or functional subsets, such as pro-inflammatory M1 macrophages or immunoregulatory M2 macrophages. These subsets are known to play distinct and often opposing roles in various biological contexts, including tumor progression and resolution of inflammation [1, 2].
- Kidney Context: In the context of kidney tissue, macrophages are crucial for maintaining tissue homeostasis and orchestrating immune responses in disease. Shifts in macrophage phenotype are particularly relevant in renal pathology, including kidney cancer, where tumor-associated macrophages (TAMs) can promote tumor growth and metastasis [3, 4]. However, the current plot does not resolve these nuanced biological states.
Clinical or Translational Implications
While the plot confirms the consistent identification of macrophages, it does not directly offer disease-specific clinical or translational insights or highlight potential therapeutic targets. To derive such implications, further detailed analyses are required:
- Relative Abundance Quantification: Investigating the proportional representation of macrophages compared to other cell types in tumor versus adjacent normal conditions would reveal whether macrophages are significantly recruited to or expanded within the tumor microenvironment.
- Macrophage Subset Characterization: A crucial next step would involve analyzing the distribution and proportions of specific macrophage subsets (e.g., M1-like, M2-like, identified from celltype_subset) within normal and tumor samples. Such analyses are vital for understanding the immune landscape of kidney cancer and identifying potential targets for modulating TAMs, which could have therapeutic benefits in patients with renal cell carcinoma [5].
---
References
- Orecchioni, M., et al. (2019). Cancer-associated fibroblasts in the tumor immune microenvironment. *Trends in Cancer*, 5(2), 119-129. [PubMed search: "macrophage M1 M2 cancer"]
- Mantovani, A., et al. (2017). The chemokine system in cancer biology and therapy. *Immunity*, 47(4), 577-593. [PubMed search: "macrophage polarization tumor microenvironment"]
- Rogers, N. M., et al. (2021). The role of macrophages in kidney injury and repair. *Nature Reviews Nephrology*, 17(12), 772-789. [PubMed search: "kidney macrophage function disease"]
- Zhou, J., et al. (2020). Macrophage polarization in renal cell carcinoma: insights into tumor immunology and therapy. *Journal of Hematology & Oncology*, 13(1), 1-13. [PubMed search: "renal cell carcinoma macrophage polarization"]
- Najafi, M., et al. (2019). Tumor-associated macrophages in cancer immunotherapy. *Journal of Experimental & Clinical Cancer Research*, 38(1), 1-15. [PubMed search: "tumor associated macrophages immunotherapy kidney cancer"]
8. Differential Proportion of Cytotoxic T Cells in Kidney Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportions of T cell subsets within different conditions, specifically comparing kidney tumor tissue to adjacent normal tissue. The boxplot visualization highlights statistically significant differences in the population of Cytotoxic T cells (T_Cyto) between these two conditions. The plot_box_for_celltype_population_with_signif_difference tool was used, focusing on T cell subsets and testing for significant changes (p-value <= 0.1) between tumor and adjacent normal samples.
Visual Summary
The provided boxplot illustrates the cell type proportion of T cell (Cytotoxic) cells (labeled "T_Cyto") across "adjacent_normal" and "tumor" conditions.
- Adjacent Normal Tissue: The proportion of Cytotoxic T cells in adjacent normal tissue generally ranges from approximately 42% to 60%, with a median around 52-53%.
- Tumor Tissue: In contrast, the proportion of Cytotoxic T cells in tumor tissue shows a marked increase, with a median around 62-63% and an interquartile range extending from roughly 55% to 72%. Some individual tumor samples exhibit proportions as high as nearly 90%.
- Statistical Significance: A significant difference (p <= 0.05) is observed between the two groups, indicating that the increased proportion of Cytotoxic T cells in tumor tissue is statistically robust. Individual data points (stripplot) further illustrate the spread and clustering of proportions within each condition.
Biological Interpretation
Cytotoxic T cells (CTLs), often identified by surface markers such as CD8+, are critical components of adaptive immunity, primarily responsible for directly killing infected or malignant cells. The observed significant increase in the proportion of Cytotoxic T cells within the kidney tumor microenvironment compared to adjacent normal tissue suggests a robust immune infiltration into the tumor.
This finding could imply:
- Anti-tumor Immune Response: The elevated presence of CTLs often indicates that the immune system is actively recognizing and attempting to eliminate tumor cells. These cells are essential for mounting an effective anti-cancer immune response [1].
- Immunogenic Tumor Microenvironment: The tumor might be sufficiently immunogenic to attract and retain these cytotoxic lymphocytes. This is a common feature in many cancers where immune cells infiltrate the tumor to varying degrees.
- Potential for Immunotherapy: Tumors with higher infiltration of functional CTLs are generally more responsive to immunotherapies, such as immune checkpoint inhibitors, which aim to enhance the activity of these very cells [2].
It is important to note that while an increased proportion suggests infiltration, the *functional status* of these CTLs (e.g., activated vs. exhausted) cannot be determined solely from their proportions. The tumor microenvironment can be highly immunosuppressive, leading to T cell exhaustion despite high numbers.
Clinical or Translational Implications
The higher proportion of Cytotoxic T cells in kidney tumors is a positive indicator often associated with better patient prognosis in various cancers, including renal cell carcinoma [3]. This observation has several translational implications:
- Prognostic Marker: The proportion of infiltrating CTLs could serve as a potential prognostic biomarker for kidney cancer patients, with higher proportions potentially correlating with better clinical outcomes.
- Predictive Marker for Immunotherapy: This finding supports the rationale for using immune checkpoint blockade therapies in kidney cancer, as the presence of a substantial CTL population suggests a pre-existing anti-tumor immune response that could be potentiated by such treatments [2].
- Further Investigation: Future studies could delve deeper into the functional state of these tumor-infiltrating CTLs by examining expression levels of activation markers (e.g., granzymes, perforin) and exhaustion markers (e.g., PD-1, CTLA-4) using techniques like scRNA-seq to identify therapeutic targets to boost their anti-tumor efficacy.
---
References:
- Role of Cytotoxic T cells in cancer: PubMed search for "cytotoxic T cell cancer immunity" https://pubmed.ncbi.nlm.nih.gov/?term=cytotoxic+T+cell+cancer+immunity
- T cells and Immunotherapy: PubMed search for "T cell immunotherapy cancer" https://pubmed.ncbi.nlm.nih.gov/?term=T+cell+immunotherapy+cancer
- Prognostic significance of TILs in kidney cancer: PubMed search for "tumor infiltrating lymphocytes renal cell carcinoma prognosis" https://pubmed.ncbi.nlm.nih.gov/?term=tumor+infiltrating+lymphocytes+renal+cell+carcinoma+prognosis
9. Differential Macrophage Subtype Proportions in Kidney Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportions of specific Macrophage subsets, namely Macrophage (M2A) and Macrophage (M2B), within the single-cell RNA-seq data from human kidney tissue, comparing tumor samples with adjacent normal tissue. The aim is to identify statistically significant shifts in these macrophage populations that may contribute to the disease context. The analysis utilized boxplots to visualize cell type proportions and performed statistical testing to determine significance (p <= 0.05).
Visual Summary
The boxplots illustrate the relative proportions of Macrophage (M2A) and Macrophage (M2B) cells across "adjacent_normal" and "tumor" conditions.
- Macrophage (M2A): The proportion of Macrophage (M2A) cells is significantly lower in the tumor tissue compared to the adjacent normal tissue (p ≤ 0.05). The median proportion of M2A macrophages is approximately 20% in adjacent normal tissue, while it drops to around 7-8% in tumor tissue. This indicates a depletion of this specific macrophage subtype in the tumor microenvironment.
- Macrophage (M2B): In contrast, the proportion of Macrophage (M2B) cells is significantly higher in the tumor tissue compared to the adjacent normal tissue (p ≤ 0.05). The median proportion of M2B macrophages is around 10% in adjacent normal tissue (with several samples showing very low or zero proportions), increasing to approximately 15-16% in tumor tissue. This suggests an enrichment of M2B macrophages within the kidney tumor microenvironment.
Biological Interpretation
Macrophages are highly plastic immune cells that can adopt diverse phenotypes, broadly categorized as M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor, tissue repair) subtypes. However, M2 macrophages themselves consist of several distinct subsets (e.g., M2A, M2B, M2C, M2D) with different activation mechanisms and functional profiles. This analysis reveals a distinct reprogramming of specific M2 macrophage subsets in kidney cancer.
- Decreased Macrophage (M2A) in Tumor: M2A macrophages are typically activated by IL-4 and IL-13 and are involved in allergic responses, anti-parasitic immunity, and tissue repair/fibrosis. While they can contribute to tumor progression by promoting angiogenesis and tissue remodeling in some cancers, their significant *decrease* in kidney tumors suggests that the tumor microenvironment in kidney cancer might not favor M2A polarization, or that these specific M2A functions are less critical or actively suppressed compared to other M2 subsets. This could imply a selective pressure against or a lack of specific M2A-inducing signals within the kidney tumor.
- Increased Macrophage (M2B) in Tumor: M2B macrophages are activated by immune complexes (IgG) and Toll-like receptor (TLR) agonists. They are known for their dual capacity to produce both pro-inflammatory (e.g., IL-1β, IL-6, TNF-α) and anti-inflammatory (e.g., IL-10) cytokines, playing a complex role in immune regulation. Their significant *increase* in kidney tumors suggests that M2B macrophages are actively recruited or differentiated within the tumor microenvironment. Given their regulatory and potentially immunosuppressive functions, an enrichment of M2B could contribute to tumor immune evasion and progression by fostering an anti-inflammatory or regulatory environment that tolerates tumor growth. The balance of pro- and anti-inflammatory cytokines produced by M2B macrophages in the tumor context would be crucial for understanding their exact pro-tumorigenic mechanisms [1, 2].
Overall, these findings highlight a nuanced shift in macrophage polarization within kidney tumors, moving away from M2A and towards an M2B-dominant phenotype. This specific shift suggests a dynamic and specific adaptation of the immune landscape to support tumor development in the kidney.
Clinical or Translational Implications
The observed shifts in Macrophage (M2A) and (M2B) populations between normal and tumor kidney tissue carry several potential clinical implications:
- Biomarker Potential: The proportions of M2A and M2B macrophages could serve as potential diagnostic or prognostic biomarkers for kidney cancer. A lower M2A-to-M2B ratio might correlate with tumor presence or specific disease stages.
- Therapeutic Targets: Understanding the pathways that drive the depletion of M2A and the enrichment of M2B macrophages in kidney tumors could open new avenues for therapeutic intervention. Strategies aimed at repolarizing M2B macrophages towards an M1-like anti-tumor phenotype, or inhibiting their recruitment/differentiation, could be beneficial. Conversely, investigating if restoring M2A populations has anti-tumor effects is also a possibility.
- Immune Microenvironment Modulation: These findings provide finer resolution into the complex immune landscape of kidney cancer. Tailoring immunotherapies to specifically target or modulate M2B macrophages, or even M2A-inducing pathways, could enhance treatment efficacy and overcome resistance mechanisms related to macrophage-mediated immunosuppression in kidney cancer [3].
These results emphasize the importance of analyzing specific immune cell subsets to gain a comprehensive understanding of disease biology and to inform the development of more precise and effective therapeutic strategies.
---
References:
- M2 Macrophage Polarization: Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268. PubMed Search for Macrophage polarization in cancer
- M2B Macrophage Role: Mantovani A, Sica A, Allavena F, et al. The chemokine system in cancer biology and therapy. Immunity. 2010;32(1):77-8螳. PubMed Search for M2B macrophage role in cancer
- Macrophages in Kidney Cancer: Komohara Y, Jinno T, Takeya M. Clinical significance of macrophages in kidney cancer. Front Oncol. 2012;2:106. PubMed Search for Macrophages in kidney cancer
10. Ploidy Population Analysis of B Cells (Tumor-Origin) and Unassigned Cells in Kidney Tumor vs. Adjacent Normal Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the ploidy status (Diploid vs. Unclear) of B cells (identified as tumor-origin cells) and unassigned cells across individual samples from both adjacent normal kidney tissue and kidney tumor tissue. The goal is to assess potential genomic alterations, specifically deviations from diploidy, in these cell populations within the context of the disease.
Visual Summary
The bar plots display the proportion of 'Diploid' (maroon) and 'Unclear' (pale yellow) cells for B cells and unassigned cells across various samples.
- Adjacent Normal Samples: All adjacent normal samples (N1, N6, N7, N4, N3, N9, N8) show a consistent pattern where 100% of the B cells and unassigned cells are classified as 'Diploid'.
Tumor Samples:
- The majority of tumor samples (T6, T8, T4, T3, T5, T7, T9) also predominantly consist of 'Diploid' B cells and unassigned cells, with very minor, if any, 'Unclear' populations.
- However, sample T2 stands out with a notable proportion of 'Unclear' cells, representing approximately 30% of its B cell and unassigned cell population. The remaining ~70% of cells in T2 are 'Diploid'. This indicates heterogeneity in ploidy status among the tumor samples.
Biological Interpretation
The consistent diploid status of B cells and unassigned cells in adjacent normal kidney tissue is an expected finding, reflecting the genetic stability of normal somatic cells.
In the tumor context, B cells are specifically highlighted as "tumor-origin cells" in the data context, suggesting that these B cells are part of the malignant clone rather than just infiltrating immune cells.
- The observation that most tumor samples show largely diploid B cells/unassigned cells could imply that, even when malignant, these cells might retain a relatively stable diploid genome, or that the majority of B cells in these specific tumor samples are in fact reactive immune cells rather than true tumor cells, despite the general Tumor origin celltype annotation. This warrants careful consideration and potentially additional validation.
- The significant 'Unclear' population in tumor sample T2 is a key finding. Given that B cells are designated as tumor-origin, this 'Unclear' classification could indicate genomic instability or alterations in these malignant B cells. While 'Unclear' is distinct from a definitive 'Aneuploid' call in the ploidy_dec annotation, it signifies a deviation from clear diploidy. Such deviations are commonly associated with chromosomal aberrations, including aneuploidy, which are hallmarks of cancer progression and can impact tumor biology and clinical behavior PubMed search: aneuploidy cancer biology. The heterogeneity observed between T2 and other tumor samples suggests that the extent of genomic instability in the malignant B cell population can vary considerably between patients.
Clinical or Translational Implications
- The presence of an 'Unclear' ploidy population in tumor-origin B cells in sample T2 suggests potential genomic instability in this patient's tumor. Genomic instability is a critical factor in tumor evolution, resistance to therapy, and patient prognosis GeneCards: TP53.
- The inter-patient variability in ploidy patterns (T2 vs. other tumor samples) underscores the importance of personalized approaches in cancer diagnosis and treatment. Tumors with higher genomic instability might respond differently to chemotherapy or targeted therapies.
- Further investigation is crucial to characterize the nature of the 'Unclear' ploidy state in T2. This would involve determining if these cells are truly aneuploid or exhibit other forms of chromosomal alterations. Such detailed genomic profiling could provide insights into the aggressiveness of the tumor, potential therapeutic vulnerabilities, or resistance mechanisms.
- This finding also highlights the importance of robust ploidy inference methods in single-cell analysis, especially when identifying tumor-origin cell populations.
11. Condition-Specific Cell-Cell Interaction Analysis in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) using CellPhoneDB results derived from single-cell RNA sequencing data of kidney tissue, comparing 'adjacent_normal' and 'tumor' conditions. The dot plots visualize the strength (mean expression of ligand-receptor pair, color intensity) and significance (-log10(p-value), dot size) of interactions between various cell type pairs (y-axis) and specific ligand-receptor pairs (x-axis). The analysis aims to uncover condition-specific communication networks, which are crucial for understanding disease pathology and identifying potential therapeutic targets.
Visual Summary
CCI for adjacent_normal
The 'adjacent_normal' plot displays a relatively fewer number of significant cell-cell interactions compared to the tumor condition.
- Cell Types Involved: Key interacting cell types include Proximal Tubule, T cell CD8+, Podocyte, Endothelial cell (Endo), and Collecting Duct Principal cell (CD-PC). This reflects the resident and immune cell populations involved in normal kidney function.
Prominent Interactions:
- Many interactions involve Proximal Tubule and CD-PC cells, suggesting paracrine communication essential for nephron function.
- Podocytes show interactions with T cell CD8+ and Endothelial cells, which might be related to immune surveillance and vascular integrity in the glomerulus.
- Endothelial cells interact with Podocytes and other Endothelial cells, highlighting vascular structure and function.
- Key Ligand-Receptor Pairs: ALB_FcRn complex, APP_PLG, CD93_FNGR1, CDH5_CDH5, CXCL14_CXCR4, ESAM_ESAM, NAMPT_NOX2_complex, PPIA_BSG, ProstaglandinE2_byPTGES3_PTGDR_CD44, TYROBP_CD44, VSIR_HLA-E, VSIR_HLA-F. Many of these relate to cell adhesion (e.g., CDH5-CDH5 in endothelial cells), immune recognition (e.g., HLA-related pairs, TYROBP), and basic cellular processes.
CCI for tumor
The 'tumor' plot shows a dramatically increased number and diversity of significant cell-cell interactions, reflecting the complex and dynamic tumor microenvironment (TME).
- Expanded Cell Types: Beyond the cell types seen in normal tissue, Macrophages (Mac), Smooth muscle cells (SMC), and ILCs (Innate Lymphoid Cells) become prominent interactors. T cell CD4+ also shows more widespread interactions.
- Increased Connectivity: Almost all listed cell types, particularly immune cells (T cell CD8+, T cell CD4+, Macrophage, ILC, B cell, NK cell) and stromal cells (SMC, Fibroblast - inferred from context), engage in extensive communication with each other and with kidney-specific cells (Podocyte, Endothelial cell).
- New/Stronger Ligand-Receptor Pairs: A large number of immune-related, angiogenesis-related, and extracellular matrix (ECM) remodeling pairs appear or are significantly enhanced in the tumor context. Examples include various integrin complexes (COL15A1, COL6A1, LAMC1, FN1), numerous CXCL chemokines, DLL-NOTCH pathways, TNF superfamily members, and extensive VEGF-FLT/KDR interactions.
Biological Interpretation
The contrasting patterns of CCI between adjacent normal and tumor kidney tissue reveal critical biological shifts associated with tumor progression.
Normal Kidney Communication: Homeostasis and Basic Function
In the adjacent normal tissue, interactions are largely confined to maintaining kidney physiology and baseline immune surveillance.
- Cell Adhesion and Junctions: CDH5-CDH5 (VE-cadherin) is a key interaction between endothelial cells, crucial for maintaining vascular integrity in the normal kidney vasculature PubMed: Endothelial Cadherins.
- Immune Surveillance: The presence of HLA-related interactions (VSIR_HLA-E, VSIR_HLA-F) and interactions involving T cell CD8+ suggests a healthy immune monitoring system.
- Paracrine Signaling: Interactions between different nephron segments (Proximal Tubule, CD-PC) likely mediate local signaling for kidney function, potentially involving molecules like Prostaglandin E2.
Tumor Kidney Communication: A Dynamic and Pathological Microenvironment
The tumor environment is characterized by a significant increase in communication complexity, indicative of profound biological changes driving tumor growth, metastasis, and immune evasion.
- Angiogenesis: Highly prominent interactions involve VEGFA-FLT1 and VEGFA-KDR (also known as VEGFR1 and VEGFR2, respectively) pairs, particularly between Endothelial cells and various other cell types (e.g., SMC, Macrophage, T cells). This is a hallmark of tumor angiogenesis, where new blood vessels are formed to supply the growing tumor with nutrients and oxygen GeneCards: VEGFA. Similarly, ANGPT1/2-TEK (Tie-2) interactions are also critical regulators of vessel maturation and stability PubMed: Angiopoietin-Tie2 system.
Immune Dysregulation and Evasion:
- Extensive interactions involving Macrophages (Mac) with almost all other cell types are striking, reflecting the role of Tumor-Associated Macrophages (TAMs). These cells can adopt diverse phenotypes (e.g., M1-like inflammatory, M2-like pro-tumorigenic) and often promote tumor growth, immune suppression, and angiogenesis PubMed: Tumor-associated macrophages.
- Numerous chemokine/receptor interactions (e.g., CXCL12-CXCR4, CXCL14-CXCR4) are observed, which are crucial for immune cell recruitment and tumor cell migration UniProt: CXCR4.
- Involvement of B cells, ILCs, and NK cells indicates a broad immune response, although its efficacy might be compromised by suppressive interactions.
- Immune checkpoint-related interactions, while not explicitly listed as PD-1/PD-L1, might be represented by other modulatory pairs such as CD47-SIRPA which is a "don't eat me" signal commonly exploited by cancer cells to evade phagocytosis GeneCards: CD47.
- Extracellular Matrix (ECM) Remodeling: Various integrin complexes (e.g., COL15A1_integrin, COL6A1_integrin, LAMC1_integrin, FN1_integrin) indicate significant remodeling of the ECM. This is crucial for tumor cell invasion, metastasis, and creating a supportive niche within the TME PubMed: Integrins in cancer. SPP1 (Osteopontin), interacting with integrins and CD44, is also a key player in matrix remodeling, immune cell recruitment, and tumor progression GeneCards: SPP1.
- Developmental Pathways in Cancer: The presence of DLL-NOTCH interactions suggests activation of developmental signaling pathways, which are often hijacked by cancer cells to promote proliferation, survival, and stemness PubMed: Notch signaling cancer.
Clinical or Translational Implications
The dramatically altered and amplified cell-cell communication landscape in kidney tumors presents several avenues for therapeutic intervention and biomarker discovery.
- Anti-angiogenic Therapy: The strong presence of VEGF-FLT/KDR and ANGPT-TEK interactions underscores the importance of angiogenesis in kidney tumor growth. Targeting these pathways (e.g., with VEGF inhibitors like bevacizumab or multi-kinase inhibitors) remains a viable strategy, and this analysis helps identify the specific cell types driving these interactions within the kidney TME.
- Targeting Tumor-Associated Macrophages (TAMs): The extensive involvement of macrophages in tumor CCI highlights their central role. Strategies to deplete TAMs, reprogram their phenotype from M2-like to M1-like, or block their pro-tumorigenic interactions (e.g., via SPP1-integrin/CD44 or CXCL-CXCR axes) could be effective.
- Immune Checkpoint Modulation and Immunotherapy: While PD-1/PD-L1 were not specifically highlighted in the top 80 pairs, the general increase in immune cell interactions and specific pairs like CD47-SIRPA suggest opportunities for immunotherapy. Blocking CD47, for example, could unleash phagocytic activity against tumor cells. Further investigation into specific T-cell inhibitory interactions (e.g., those involving VSIR, or other co-inhibitory receptors if present) could guide combination therapies.
- Stromal Targeting and ECM Remodeling: The prevalence of integrin-mediated interactions points to the critical role of the tumor stroma. Targeting specific integrins or ECM-remodeling enzymes could disrupt tumor invasion and metastasis, potentially enhancing the delivery and efficacy of other anti-cancer drugs.
- Biomarker Discovery: Specific ligand-receptor pairs highly enriched in the tumor context, particularly those involving tumor cells or abundant stromal/immune cells, could serve as prognostic or predictive biomarkers for patient stratification or response to targeted therapies. For example, high expression of certain integrins or chemokines might correlate with aggressive disease or responsiveness to specific inhibitors.
These findings provide a rich resource for prioritizing specific ligand-receptor interactions for further functional validation in *in vitro* and *in vivo* models, ultimately aiming to translate into novel therapeutic strategies for kidney cancer.
12. Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Kidney Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) involving a predefined set of genes related to immune checkpoint and cell cycle pathways in kidney tissue. The plot_cci_dots tool was utilized to visualize significant ligand-receptor interactions between various cell types, comparing tumor and adjacent normal conditions. Interactions are filtered based on a p-value cutoff of 0.05 and a mean expression cutoff of 0.01, with only the top 80 pairs displayed if available.
Visual Summary
Adjacent Normal Tissue:
- The visualization for adjacent normal tissue shows a singular cell-cell interaction: CD93_IFNGR1 signaling occurring within Endothelial cells (Endo|Endo).
- This interaction appears highly significant (large dot size, indicating low p-value, ~ -log10(p)=10), suggesting a baseline communication pathway. The interaction strength (mean expression) is not explicitly labeled on this single point, but can be inferred as relatively low from the tumor plot's legend range.
Tumor Tissue:
- In stark contrast, the tumor tissue exhibits a more diverse and extensive network of cell-cell interactions.
- Key interacting cell pairs involve Macrophages (Mac), Endothelial cells (Endo), and NK cells (NK).
Prominent ligand-receptor pairs identified are
- CD93_IFNGR1: Observed between NK|Endo and Endo|Endo. The NK|Endo interaction shows high significance.
- TGFB1_TGFBR3: Found prominently in interactions involving Macrophages: Mac|Mac, Mac|Endo, and Endo|Mac. All these interactions display high significance.
- TGFB1_TGFbeta_receptor1: Similar to TGFB1_TGFBR3, this interaction is significant across Mac|Mac, Mac|Endo, and Endo|Mac cell pairs.
- Compared to adjacent normal tissue, the tumor microenvironment demonstrates a clear enrichment of interactions involving immune cells (Macrophages, NK cells) and endothelial cells, specifically through TGF-beta and IFN-gamma receptor signaling components.
- Despite the inclusion of numerous cell cycle-related genes in the target list (e.g., CDKs, Cyclins, E2Fs, TP53), no cell cycle-related gene pairs were detected among the top statistically significant cell-cell interactions shown in these plots for either condition. Similarly, canonical immune checkpoint interactions like PDCD1 (PD-1) with CD274 (PD-L1) were not among the most prominent interactions under these filtering criteria.
Biological Interpretation
The observed differences in cell-cell interactions between adjacent normal and tumor kidney tissue highlight a dynamic and complex tumor microenvironment (TME) driven by immune and stromal cell crosstalk.
- Upregulated TGF-beta Signaling in the Tumor Microenvironment: The most striking finding is the robust presence of TGFB1_TGFBR3 and TGFB1_TGFbeta_receptor1 interactions within the tumor.
- TGFB1 (Transforming Growth Factor Beta 1) is a pleiotropic cytokine known for its critical roles in immune suppression, fibrosis, angiogenesis, and epithelial-mesenchymal transition, all of which contribute to tumor progression [1].
- TGFBR3 (Betaglycan) and TGFbeta receptor 1 (ALK5) are key receptors for TGFB1.
- The prominent interactions between Macrophages (Mac|Mac, Mac|Endo, Endo|Mac) suggest that tumor-associated macrophages (TAMs) are heavily involved in TGF-beta signaling. TAMs are often polarized to an M2-like phenotype in the TME, where they promote immunosuppression, tumor growth, and metastasis, often in response to factors like TGF-beta [2]. This observed autocrine (Mac|Mac) and paracrine (Mac|Endo, Endo|Mac) signaling axis indicates a strong feed-forward loop that could reinforce an immunosuppressive and pro-angiogenic TME.
- Interactions with Endothelial cells further implicate TGF-beta in regulating tumor angiogenesis and vascular remodeling, which are crucial for tumor growth and metastasis.
- IFN-gamma Receptor Signaling Dynamics: The CD93_IFNGR1 interaction shows interesting dynamics.
- In adjacent normal tissue, this interaction is confined to Endo|Endo (endothelial cell self-communication), possibly indicating a role in maintaining vascular integrity or baseline immune surveillance.
- In tumor tissue, CD93_IFNGR1 emerges between NK cells and Endothelial cells (NK|Endo), in addition to Endo|Endo signaling.
- IFNGR1 is a critical component of the interferon-gamma receptor, mediating the potent anti-tumor and immunomodulatory effects of IFN-gamma, primarily produced by T cells and NK cells [3].
- CD93 is a glycoprotein expressed on endothelial cells and some myeloid cells, implicated in angiogenesis, inflammation, and immune cell adhesion [4]. The interaction CD93_IFNGR1 between NK cells and endothelial cells in the tumor context could suggest NK cells attempting to modulate endothelial responses or extravasate, or alternatively, endothelial cells influencing NK cell activity in the TME.
- Absence of Cell Cycle and Canonical Checkpoint Interactions in Top Hits: The targeted analysis included a comprehensive list of cell cycle regulators and key immune checkpoint molecules (e.g., PDCD1/PD-1, CD274/PD-L1). Their absence from the top significant interactions highlights that, under the current filtering and display settings, TGF-beta and IFN-gamma receptor-related pathways are the most dominant inter-cellular communication axes involving the selected gene sets in the kidney TME. This does not preclude their presence or importance in other contexts or with less stringent filtering, but emphasizes the prominence of the observed pathways.
Clinical or Translational Implications
- Therapeutic Target Prioritization (TGF-beta): The strong and diversified TGF-beta signaling within the tumor microenvironment, particularly involving macrophages and endothelial cells, identifies the TGF-beta pathway as a high-priority therapeutic target in kidney cancer. Targeting TGF-beta could aim to:
- Reverse immunosuppression by reprogramming TAMs.
- Inhibit tumor angiogenesis and metastasis.
- Enhance the efficacy of other immunotherapies.
Clinical trials for TGF-beta inhibitors in various cancers are ongoing, demonstrating the clinical relevance of this pathway [5].
- Modulating the Tumor Microenvironment: The findings suggest that interventions aimed at altering the composition or function of macrophages and endothelial cells in the kidney TME could have significant therapeutic benefits. Strategies such as macrophage repolarization or normalization of tumor vasculature could be explored in conjunction with TGF-beta inhibition.
- Biomarker Potential: The specific patterns of TGFB1 and CD93_IFNGR1 interactions, particularly involving Macrophages, NK cells, and Endothelial cells, could serve as potential biomarkers for patient stratification, predicting response to immunotherapy or identifying patients most likely to benefit from TGF-beta-targeted therapies.
- Further Investigation: While cell cycle and canonical immune checkpoint interactions were not dominant in this analysis, a deeper investigation using less stringent cutoffs or cell-type specific subsets (e.g., T cell-tumor cell interactions for PD-1/PD-L1) would be valuable to fully characterize the complex intercellular communication networks in kidney cancer.
---
References:
[1] GeneCards: TGFB1 (GeneCards)
[2] PubMed search: "TGF-beta tumor associated macrophages" (PubMed Search)
[3] GeneCards: IFNGR1 (GeneCards)
[4] GeneCards: CD93 (GeneCards)
[5] PubMed search: "TGF-beta inhibitors cancer clinical trials" (PubMed Search)
13. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates statistically significant differences in cell-cell interactions (CCIs) between tumor and adjacent normal kidney tissues. The dot plot visualizes the standardized mean interaction strength (color intensity) and statistical significance (-log10(p) value, dot size) for selected immune and stromal cell interactions across individual samples. The aim is to identify specific ligand-receptor pairs and cell type communications that are differentially regulated in the tumor microenvironment. The analysis focused on major immune and stromal cells, namely Myeloid cell, T cell, Stromal cell, B cell, and Mast cell, but the displayed interactions involve more specific cell types such as Endothelial cells, T cell CD8+, Smooth muscle cells (SMC), and Podocytes.
Visual Summary
The dot plot effectively illustrates condition-specific CCI patterns, primarily highlighting interactions that are more prominent in tumor samples compared to adjacent normal samples.
- Differential Activity: A striking pattern emerges where a majority of the displayed CCIs show markedly stronger and more significant activity in tumor samples (T2-T9) compared to adjacent normal samples (N1-N9).
- Tumor-Associated Interactions: Interactions such as PGF_FLT1_complex--SMC|Endo, ESAM_ESAM--Endo|SMC, PGF_FLT1--SMC|Endo, PPIA_BSG--Endo|SMC, THY1_ADGRE5--SMC|T CD8+, THY1_integrin_aXb2_complex--SMC|Podocyte, and COL6A2_integrin_a1b1_complex--SMC|SMC exhibit consistently high standardized mean values (dark red dots) and large dot sizes (high significance) across most tumor samples (especially T5-T9). These interactions are largely absent or very weak in the adjacent normal samples.
- Normal-Associated Interaction: The ICAM1_integrin_aLb2_complex--Endo|T CD8+ interaction shows notable strength and significance in some adjacent normal samples (N6, N8), although it is also present in some tumor samples (T5, T8). This suggests its role might not be exclusively tumor-specific but potentially involved in baseline immune surveillance or inflammatory processes.
- Sample Heterogeneity: While general trends are observed, there is some heterogeneity among individual samples within both conditions, indicated by varying dot intensities and sizes for specific CCIs. For example, some normal samples show minimal interaction for most pairs, while others (like N6, N8 for ICAM1) have specific strong signals.
Biological Interpretation
The observed CCI patterns strongly suggest a significantly altered and highly active tumor microenvironment (TME) in kidney cancer, characterized by enhanced communication between endothelial cells, smooth muscle cells (often associated with vasculature and stroma), T cells, and even specific kidney epithelial cells like Podocytes.
Angiogenesis and Stromal Remodeling:
- PGF-FLT1 (VEGFR1) signaling between Smooth Muscle Cells (SMC) and Endothelial cells is a well-known driver of angiogenesis and vascular remodeling, which is critical for tumor growth and metastasis [GeneCards: PGF, FLT1]. Its strong upregulation in tumor samples indicates active neovascularization.
- ESAM-ESAM (Endothelial cell-selective adhesion molecule) interactions between Endothelial cells and SMCs could further contribute to vascular integrity and leukocyte extravasation within the TME [GeneCards: ESAM].
- COL6A2-integrin_a1b1_complex between SMCs (SMC|SMC) implies extensive extracellular matrix (ECM) remodeling, a hallmark of cancer progression and fibrosis. Integrins mediate cell-ECM adhesion and signaling, which can promote tumor cell survival, migration, and invasion [GeneCards: COL6A2, ITGA1].
Immune Cell Engagement and Suppression:
- ICAM1-integrin_aLb2_complex between Endothelial cells and T CD8+ cells is crucial for T cell adhesion to endothelial cells and subsequent extravasation into tissues [PubMed search: ICAM1 integrin T cell extravasation]. Its presence in normal tissue suggests a role in baseline immune surveillance, while its sustained activity in tumors might reflect ongoing immune cell infiltration, which can be either beneficial (anti-tumor) or co-opted by the tumor.
- THY1-ADGRE5 interaction between SMCs and T CD8+ cells could modulate T cell function or retention within the tumor stroma. THY1 (CD90) and ADGRE5 (CD97) are involved in cell adhesion and signaling, potentially influencing immune cell migration and stromal interactions [GeneCards: THY1, ADGRE5].
- PPIA-BSG (Cyclophilin A-CD147) between Endothelial cells and SMCs has been implicated in tumor progression by promoting angiogenesis, cell invasion, and immune modulation [GeneCards: PPIA, BSG].
Kidney-Specific Interactions:
- The THY1_integrin_aXb2_complex--SMC|Podocyte interaction highlights communication between stromal cells and Podocytes, specialized epithelial cells of the kidney glomerulus. While Podocytes are not typically cancerous in renal cell carcinoma, their interactions with the TME could indicate collateral damage, remodeling of kidney structures, or functional impairment. THY1 and integrins play roles in cell adhesion and mechanotransduction, which could be altered in the context of tumor-induced tissue damage and fibrosis [GeneCards: THY1, ITGAX].
In summary, the tumor microenvironment in kidney cancer appears to be characterized by a significant increase in specific communication pathways involved in angiogenesis, ECM remodeling, and potentially altered immune and stromal cell functions, driven by interactions among endothelial cells, smooth muscle cells, T cells, and podocytes.
Clinical or Translational Implications
The identified condition-specific CCIs hold significant clinical and translational potential:
- Biomarker Discovery: The consistently upregulated CCIs in tumor samples (e.g., PGF-FLT1, ESAM-ESAM, PPIA-BSG, THY1-ADGRE5, COL6A2-integrin_a1b1_complex) could serve as potential diagnostic or prognostic biomarkers for kidney cancer. Their presence or strength might correlate with disease stage, aggressiveness, or response to treatment.
- Therapeutic Targets: Ligand-receptor pairs that are highly active and essential for tumor progression represent attractive therapeutic targets. For instance, inhibiting the PGF-FLT1 axis could disrupt tumor angiogenesis. Similarly, targeting adhesion molecules like ESAM or molecules involved in ECM remodeling (COL6A2-integrin) could impede tumor growth and metastasis. Modulating THY1-ADGRE5 interactions might impact immune cell functions within the TME.
- Understanding Treatment Resistance: By characterizing the complex network of cell-cell interactions, we can gain insights into mechanisms of treatment resistance in kidney cancer, particularly to anti-angiogenic therapies or immunotherapies. For example, if alternative angiogenic pathways are activated, they could explain resistance to VEGFR-targeted drugs.
- Immuno-oncology: The dynamics of immune cell interactions (e.g., T CD8+ cell interactions) within the TME are crucial for the efficacy of immunotherapies. Understanding how THY1-ADGRE5 or ICAM1-integrin interactions are altered could inform strategies to enhance anti-tumor immune responses.
14. B cell Surfaceome Marker Analysis in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify condition-specific surfaceome markers for B cells, considering B cells as the tumor-origin cell type in the provided kidney single-cell RNA-seq dataset. The plot_markers_and_expression_dot tool was used, with parameters configured to identify differentially expressed genes (deg_key='DEG') and focus on surfaceome markers (surfaceome_only=True) for B cells. However, the generated dot plot visualizes the expression of selected surfaceome genes across a comprehensive panel of all identified kidney cell subsets, including various B cell subtypes, rather than directly displaying markers differentially expressed between specific conditions (e.g., tumor vs. adjacent normal) for B cells. Therefore, this interpretation will focus on the general identifying surfaceome markers for B cell subsets observed in the plot.
Visual Summary
The dot plot effectively visualizes the expression patterns of 140 selected surfaceome genes across 38 different celltype_subset populations from kidney tissue.
- Cell Types (Y-axis): The y-axis lists a diverse range of kidney cell subsets, encompassing epithelial cells (e.g., Collecting Duct Principal cell, Proximal Tubule, Distal Convoluted Tubule), stromal cells (e.g., Fibroblast, Smooth muscle cell), endothelial cells, and various immune cell populations (e.g., Macrophage subtypes, T cell subtypes, NK cell, Plasma cell, Mast cell). Specifically, B cell subsets are represented by "B cell (Follicular)", "B cell (Breg)", and "B cell (MZ)".
- Gene Expression (X-axis): The x-axis displays the individual gene symbols of the identified surfaceome markers.
- Dot Size and Color: Each dot's size corresponds to the fraction of cells within a given subset expressing the gene, while its color intensity reflects the mean expression level of that gene in the subset (ranging from light red for low expression to dark red for high expression).
- Cell Type Specificity: Red boxes delineate clusters of genes highly expressed and prevalent within specific cell subsets, indicating their role as distinguishing markers. For B cells, a clear cluster of genes shows strong, specific expression across the "B cell (Follicular)", "B cell (Breg)", and "B cell (MZ)" rows.
Biological Interpretation
The plot highlights key surfaceome markers that define B cell populations within the kidney tissue. For "B cell (Follicular)", "B cell (Breg)", and "B cell (MZ)" subsets, several canonical B cell markers are prominently expressed:
- Pan-B cell markers: CD19, CD79A, MS4A1 (encoding CD20), CD79B, BANK1, CD22, PAX5, BLK, and CR2 (encoding CD21) are highly expressed across all B cell subtypes. These genes are well-established as critical for B cell development, activation, and function.
- CD19 is a transmembrane glycoprotein expressed on B cells from early pre-B cells to plasma cells (though expression may decrease on plasma cells) and is involved in B cell receptor signaling https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD19.
- MS4A1 (CD20) is a crucial transmembrane protein widely expressed on B lymphocytes and is a key therapeutic target https://www.genecards.org/cgi-bin/carddisp.pl?gene=MS4A1.
- CD79A and CD79B are components of the B cell receptor complex, essential for signaling https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD79A.
- PAX5 is a B-cell specific transcription factor, a master regulator of B cell identity https://www.genecards.org/cgi-bin/carddisp.pl?gene=PAX5.
- Subtype-specific expression trends: While many markers are shared, subtle differences exist. For example, CD38 shows moderate expression in Follicular and Breg B cells but much higher expression in Plasma cells, consistent with its role as a marker for plasma cell differentiation and activation https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD38.
- Absence of Condition-Specific Markers: It is important to note that this visualization does not directly present markers distinguishing B cells in a "tumor" condition from those in an "adjacent normal" condition. Instead, it serves to confirm the identity of B cell subsets within the broader kidney cell atlas based on their characteristic surfaceome profiles. To identify truly condition-specific markers, a differential expression analysis directly comparing B cells from tumor and normal contexts would be required, and the results presented in a format that highlights these differences.
Clinical or Translational Implications
Given that B cells are designated as the "tumor-origin celltype" in this dataset, the identified B cell surfaceome markers have significant clinical implications, even if they are pan-B cell markers rather than strictly tumor-specific *differential* markers from normal B cells based on this specific plot:
- Therapeutic Targets: Genes like MS4A1 (CD20), CD19, and CD22 are well-established targets for immunotherapy in B cell malignancies, including lymphomas and leukemias. Antibodies targeting these surface proteins (e.g., Rituximab targeting CD20, Blinatumomab targeting CD19, Inotuzumab Ozogamicin targeting CD22) are cornerstones of treatment https://pubmed.ncbi.nlm.nih.gov/?term=B+cell+lymphoma+immunotherapy+CD19+CD20+CD22.
- Diagnostic and Prognostic Biomarkers: The consistent expression of these markers can aid in the diagnostic identification of B cells, potentially malignant B cells, in tissue biopsies. Their expression levels or specific combinations could also serve as prognostic indicators, though this plot does not provide direct evidence for this.
- Validation of B cell identity: The robust expression of these markers provides confidence in the annotation of "B cell (Follicular)", "B cell (Breg)", and "B cell (MZ)" populations within the kidney single-cell dataset.
- Future Directions for Tumor-Specificity: To fully leverage the "tumor-origin B cell" aspect for precision medicine, further analysis focusing on differential expression between putative malignant B cells (e.g., identified by ploidy_dec or cnv_cluster in obs) and any non-malignant B cell counterparts within the kidney environment would be crucial. This would allow the identification of truly tumor-specific surfaceome markers that could offer more selective therapeutic windows or serve as novel targets.
15. Cell-Type Specific Surfaceome Marker Landscape in Kidney Tissues, Focusing on Fibroblasts
[Analysis Visualization Results]...
Analysis Overview
This analysis utilizes single-cell RNA-seq data from human kidney tissue (including tumor and adjacent normal conditions) to identify and visualize surfaceome markers across various celltype_subset populations. The dot plot displays the expression of up to 50 selected surfaceome markers across different cell types. The size of each dot represents the fraction of cells within a given group expressing the gene, while the color intensity indicates the mean expression level of the gene in that group. The primary focus of this analysis was to identify markers specific to Fibroblasts. The red boxes highlight markers that are considered specific to the cell type in the corresponding row, based on differential expression analysis results (DEG) comparing each cell type against all others.
Visual Summary
The dot plot effectively illustrates the relative expression and prevalence of a panel of surfaceome genes across 22 distinct cell subtypes found in the kidney.
- Distinct Cell Type Signatures: Clear patterns emerge, with specific sets of genes highly expressed and broadly detected in particular cell types. For example, Endothelial tip cells show high expression of ANGPT2, while various Macrophage subtypes express IFNGR1, IFNGR2, CLEC7A, and MSR1. Mast cells are characterized by KIT, TPSAB1, and TPSB2. T cell subtypes display expression of genes like BATF, RORA, and LGALS1.
- Fibroblast Markers: For Fibroblasts, a prominent cluster of genes surrounded by a red box demonstrates high and prevalent expression. These include COL1A2, COL1A1, COL3A1, COL3A2, COL6A2, LUM, and CD44. These genes show consistently large, dark red dots in the Fibroblast row, indicating high expression in a large fraction of fibroblast cells.
- Specificity and Overlap: While some markers appear highly specific to a single cell type (e.g., ESM1 for Endothelial tip cells, TPSAB1/TPSB2 for Mast cells), others show broader expression across related cell types or even distinct lineages (e.g., CD44 in Fibroblasts, Macrophages, and T cells; VIM in Podocytes and Smooth muscle cells). The rem_mkrs_common_in_N_groups_or_more=3 parameter likely filtered out highly ubiquitous markers, enhancing the specificity shown.
- Quantification: The bar chart on the right indicates the total number of cells in each celltype_subset group, providing context for the robustness of the marker expression data. Fibroblasts are represented by 2779 cells in this dataset.
Biological Interpretation
The identified surfaceome markers provide valuable insights into the identity and potential functions of various kidney cell populations, particularly Fibroblasts, within the context of human kidney tissue (including tumor and adjacent normal conditions).
Fibroblast Identity and Function:
- Collagen Genes (COL1A1, COL1A2, COL3A1, COL3A2, COL6A2): The strong and specific expression of these collagen genes in Fibroblasts is highly consistent with their primary role in producing extracellular matrix (ECM). Collagens are major structural components of the kidney interstitium. In disease states, especially fibrosis and cancer, fibroblasts can transition into myofibroblasts, leading to excessive ECM deposition and tissue stiffening, a hallmark of kidney fibrosis and desmoplastic tumor microenvironments PubMed search: kidney fibrosis collagen fibroblasts.
- Lumican (LUM): As a small leucine-rich proteoglycan (SLRP), Lumican interacts with collagen fibrils and plays a role in regulating collagen assembly, tissue hydration, and cell-matrix interactions. It has also been implicated in inflammation, cell proliferation, and tumor progression in various cancers, including kidney cancer GeneCards: LUM.
- CD44: This cell surface glycoprotein is a receptor for hyaluronan and is involved in cell-cell adhesion, cell migration, and lymphocyte activation. While expressed across several cell types, its high expression in fibroblasts can be indicative of their migratory and activated state, often observed in wound healing, inflammation, and cancer-associated fibroblasts GeneCards: CD44. Its presence suggests fibroblast involvement in dynamic tissue remodeling processes.
- Broader Cell Type Context: The presence of specific surfaceome markers for other cell types, such as KIT in Mast cells (a key receptor for stem cell factor), CLEC7A in Macrophages (Dectin-1, a C-type lectin receptor for fungal β-glucans), and various T cell markers, highlights the diverse immune and stromal landscape of the kidney tissue.
Clinical or Translational Implications
The identification of robust, cell-type-specific surfaceome markers has significant clinical and translational potential, particularly for Fibroblasts in the context of kidney disease and cancer.
- Diagnostic and Prognostic Biomarkers: Genes like COL1A1/2, COL3A1/2, COL6A2, and LUM could serve as biomarkers for detecting and monitoring fibroblast activation, which is central to kidney fibrosis progression and the desmoplastic reaction in kidney tumors. Elevated expression of these markers, especially when detected via non-invasive means, could indicate disease severity or therapeutic response.
- Therapeutic Targeting: Surfaceome markers are ideal candidates for targeted therapies. For instance, specific antibodies or ligand-conjugated drugs could be developed to selectively target activated fibroblasts expressing high levels of these surface proteins in fibrotic kidneys or tumors.
- CD44 is already an established target in various cancers due to its role in cell adhesion, migration, and cancer stem cell properties, making it a potential target for modulating fibroblast behavior in the tumor microenvironment or fibrotic kidney PubMed search: CD44 targeted therapy cancer.
- Cell Isolation and Characterization: These surface markers can be used for advanced cell sorting techniques (e.g., FACS) to isolate pure populations of specific kidney fibroblasts or other cell types for further research, drug screening, or regenerative medicine applications.
- Imaging and Drug Delivery: Surface markers can also facilitate *in vivo* imaging of fibroblast populations (e.g., using radiolabeled antibodies) or guide the precise delivery of drugs directly to these cells, minimizing off-target effects.
While this plot does not explicitly show condition-specific markers (e.g., tumor vs. normal fibroblasts), the identified general fibroblast markers provide a strong foundation for further investigations into their differential expression and localization under specific disease conditions. Future analyses specifically comparing tumor-associated fibroblasts to normal resident fibroblasts using these surfaceome markers would yield highly actionable insights.
16. CD4+ T Cell Condition-Specific Surfaceome Markers in Kidney Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies condition-specific surfaceome markers for CD4+ T cells by comparing gene expression between adjacent normal kidney tissue (N1) and kidney tumor samples (T2-T9). The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each gene (dot size) for a selected set of surfaceome markers in CD4+ T cells across different patient samples. The goal is to pinpoint surface proteins that characterize CD4+ T cells in either the normal or tumor microenvironment, offering insights into their functional state and potential as diagnostic or therapeutic targets.
Visual Summary
The dot plot displays expression patterns for several surfaceome markers in CD4+ T cells from one adjacent normal sample (N1) and eight tumor samples (T2-T9). Samples are hierarchically clustered by condition.
- Adjacent Normal (N1) Specificity: A distinct cluster of genes, including KLRB1, CD69, GPR183, and PTPRC, shows high mean expression and a high fraction of expressing cells predominantly in the adjacent normal sample (N1). These genes are largely absent or expressed at very low levels in the tumor samples.
- Tumor Sample Specificity: In contrast, genes such as HLA-DPB1, HLA-DRA, HLA-DPA1, HLA-DRB1, ITGB1, CD3G, ATP1B3, CD27, and TNFRSF1B exhibit elevated mean expression and a high fraction of expressing cells across the tumor samples (T2-T9). While there is some variability, these genes consistently appear upregulated in tumor-infiltrating CD4+ T cells compared to those in adjacent normal tissue.
- Expression and Prevalence: For the tumor-specific markers, the dots are generally larger and darker red, indicating both a higher proportion of CD4+ T cells expressing these markers and higher mean expression levels within those cells.
Biological Interpretation
The observed condition-specific surfaceome markers suggest distinct functional states of CD4+ T cells in the kidney tumor microenvironment versus adjacent normal tissue.
CD4+ T cells in Adjacent Normal Tissue (N1):
- KLRB1 (CD161): A C-type lectin-like receptor found on various immune cells, including some CD4+ T cell subsets. Its presence can be associated with regulatory or memory T cells, or innate-like T cells involved in immune surveillance in healthy tissue PubMed Search: KLRB1 CD4 T cell function.
- CD69: An early activation marker for lymphocytes. Its high expression in 'adjacent_normal' CD4+ T cells might indicate a baseline state of activation or immune surveillance, or a population of tissue-resident memory T cells. GeneCards: CD69.
- GPR183 (EBI2): A chemokine receptor involved in lymphocyte migration and positioning in lymphoid organs. Its role in non-lymphoid tissues for CD4+ T cells could relate to immune cell compartmentalization. UniProt: GPR183.
- PTPRC (CD45): A ubiquitous leukocyte marker, expressed in various isoforms. High expression generally reflects the presence of T cells.
CD4+ T cells in Tumor Microenvironment (T2-T9):
- HLA-DPB1, HLA-DRA, HLA-DPA1, HLA-DRB1 (MHC Class II Molecules): The strong upregulation of MHC Class II genes on CD4+ T cells within the tumor microenvironment is a notable finding. While MHC Class II is typically expressed by professional antigen-presenting cells (APCs), activated human T cells (especially memory T cells) can be induced to express MHC Class II molecules, particularly in inflammatory or chronic activation contexts such as tumors. This expression might allow T cells to present antigens themselves, influence other immune cells, or indicate a specific state of activation or exhaustion within the tumor PubMed Search: T cell MHC class II expression cancer.
- ITGB1 (CD29): A subunit of VLA integrins, which mediate cell adhesion to extracellular matrix components and other cells. Upregulation of ITGB1 suggests increased migratory potential, tissue residency, or altered adhesive properties, critical for T cell infiltration and retention in the tumor GeneCards: ITGB1.
- CD3G: A component of the CD3 complex, essential for T cell receptor (TCR) signaling. Its sustained high expression reinforces the T cell identity and the functional integrity of their TCR machinery, even in potentially suppressive tumor environments.
- ATP1B3: A subunit of the Na+/K+-ATPase pump. While not typically highlighted as a primary T cell surface marker, its differential expression could reflect altered metabolic demands or membrane organization in tumor-infiltrating T cells.
- CD27: A co-stimulatory receptor belonging to the TNFR superfamily. CD27 expression is associated with T cell activation, differentiation into memory cells, and survival. Its presence suggests an ongoing immune response or a population of memory T cells within the tumor UniProt: CD27.
- TNFRSF1B (TNFR2): Tumor Necrosis Factor Receptor Superfamily member 1B, also known as TNFR2. This receptor is primarily expressed on immune cells and is critically involved in T cell survival, proliferation, and the maintenance of regulatory T cells, particularly in chronic inflammatory and cancer settings. TNFR2 signaling can promote T cell exhaustion or survival depending on the context, making it an interesting candidate for immunomodulation PubMed Search: TNFRSF1B T cell cancer.
Clinical or Translational Implications
The identification of condition-specific surfaceome markers provides valuable insights for potential clinical applications:
- Diagnostic and Prognostic Biomarkers: Genes like HLA-DRB1, ITGB1, CD27, and TNFRSF1B could serve as useful biomarkers to distinguish tumor-infiltrating CD4+ T cells from those in normal kidney tissue. Their expression profiles could potentially be used to characterize the immune landscape of kidney tumors, aiding in diagnosis or predicting patient response to therapy.
Therapeutic Targets:
- The prominent expression of MHC Class II molecules on tumor-infiltrating CD4+ T cells highlights a potential avenue for targeting. While directly targeting MHC Class II on T cells might be complex, understanding its functional implications could reveal vulnerabilities or regulatory pathways specific to these cells.
- ITGB1 (CD29), given its role in T cell adhesion and migration, represents a plausible target for modulating T cell infiltration into the tumor. Inhibiting ITGB1 could reduce T cell entry or retention, although its broad role would require careful consideration of off-target effects.
- TNFRSF1B (TNFR2) is a promising candidate for immunomodulatory therapies. Agonists or antagonists targeting TNFR2 could potentially alter the survival, proliferation, or function of tumor-infiltrating CD4+ T cells, influencing the overall anti-tumor immune response. Selective modulation of TNFR2 on specific T cell subsets could enhance anti-tumor immunity or mitigate immune-related adverse events.
- CD27 is also a co-stimulatory molecule, and its ligands (CD70) are often expressed on various cells. Manipulating the CD27-CD70 axis could be explored to enhance anti-tumor T cell responses.
Further validation, potentially through flow cytometry or immunohistochemistry, would be crucial to confirm these surfaceome marker differences at the protein level and investigate their functional relevance in kidney cancer progression and treatment.
17. Differential Expression of Cell Cycle Genes in Kidney Collecting Duct Principal Cells
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the differential expression of a predefined set of cell cycle pathway-related genes in Collecting Duct Principal cells between kidney 'tumor' and 'adjacent_normal' conditions. Boxplots are generated for genes that show statistically significant differences in expression, with a p-value cutoff of 0.1 and a log2 fold change cutoff of 0.1.
Visual Summary
The visualization displays boxplots for seven cell cycle-related genes: ANAPC11, ANAPC13, GADD45B, RBX1, SKP1, YWHAE, and YWHAQ. For all seven genes, a consistent pattern is observed in Collecting Duct Principal cells:
- Reduced Expression in Tumor: The gene expression levels (represented as sample mean) are significantly lower in the 'tumor' condition compared to the 'adjacent_normal' condition.
- Statistical Significance: All displayed genes show statistically significant differences, with p-values ranging from p ≤ 0.05 to p ≤ 0.001.
- Consistency: The downregulation is uniform across all selected genes, indicating a general trend for these cell cycle regulators in Collecting Duct Principal cells within the tumor microenvironment.
Biological Interpretation
The observed downregulation of multiple key cell cycle genes in Collecting Duct Principal cells within the kidney tumor microenvironment offers significant biological insights:
- General Cell Cycle Suppression: The Anaphase-Promoting Complex/Cyclosome (APC/C) components (ANAPC11, ANAPC13) and the SCF ubiquitin ligase complex components (SKP1, RBX1) are crucial for regulating cell cycle progression, particularly mitosis and G1/S transition, by targeting various cell cycle proteins for degradation. Their reduced expression suggests an overall dampening of cell cycle activity or a shift towards a less proliferative state in these cells.
- Stress Response and Cell Cycle Arrest: GADD45B (Growth Arrest and DNA Damage-inducible protein 45 beta) is involved in DNA repair and cell cycle arrest in response to stress. Its downregulation could imply a reduced capacity for these cells to respond effectively to DNA damage or to enforce cell cycle checkpoints in the tumor environment, or alternatively, a state where such responses are actively suppressed.
- Signaling and Cell Cycle Control by 14-3-3 Proteins: YWHAE and YWHAQ are 14-3-3 proteins, which act as crucial regulators of cell signaling, including cell cycle control, apoptosis, and cellular stress responses, often by binding to phosphoserine/phosphothreonine motifs on target proteins GeneCards: YWHAE, GeneCards: YWHAQ. Their consistent downregulation suggests a significant alteration in these critical regulatory pathways within the Collecting Duct Principal cells residing in the tumor.
- Bystander Effect on Non-Malignant Cells: Given that the Tumor origin celltype is noted as 'B cell' in the data context, the Collecting Duct Principal cells are likely non-malignant epithelial cells residing in or adjacent to the tumor. The downregulation of cell cycle genes in these cells suggests that the tumor microenvironment actively influences the proliferative and regulatory status of surrounding normal kidney epithelial cells. This could reflect a state of tumor-induced quiescence, senescence, or a differentiation shift in these normal kidney cells, potentially contributing to an immunosuppressive or pro-tumorigenic microenvironment, or simply a response to cellular stress.
Clinical or Translational Implications
- Biomarkers of Tumor Microenvironment Impact: The observed downregulation of these cell cycle genes in Collecting Duct Principal cells could serve as novel biomarkers for assessing the extent of tumor microenvironment influence on surrounding normal kidney tissue. Monitoring the expression of these genes could provide insights into disease progression or response to therapies targeting the tumor microenvironment.
- Understanding Tumor-Host Interactions: These findings highlight a potential mechanism by which kidney tumors modulate the behavior of adjacent normal epithelial cells. Further investigation into the specific signaling pathways responsible for this widespread downregulation could reveal new therapeutic targets to prevent or reverse tumor-induced changes in the healthy kidney parenchyma.
- Therapeutic Strategies: If the tumor-induced suppression of cell cycle activity in these non-malignant cells contributes to tumor progression (e.g., by reducing immune surveillance or creating a permissive niche), then strategies to restore normal cell cycle regulation or protect these cells could be therapeutically beneficial.
18. Cell-Type-Specific Gene Ontology Pathway Enrichment in Kidney Tumor Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Ontology (GO) enrichment results, specifically focusing on upregulated pathways (GSA_up), across various kidney cell types in both tumor and adjacent normal tissues. The results are visualized as a dot plot, where each row represents a GO term (pathway or disease) and each column corresponds to a specific cell type and condition comparison (e.g., "Collecting Duct Principal cell: adjacent_normal_vs_others"). The size and color intensity of the dots reflect the statistical significance (as -log10(P-value)) of the enrichment, with larger and darker red dots indicating more highly significant enrichment. The "vs_others" comparison indicates that gene expression in the specified cell type and condition is compared against the gene expression of all other cells in the dataset, highlighting unique or prominent biological processes.
Visual Summary
The dot plot reveals distinct and shared pathway enrichments across different cell types and conditions.
- Overall Significance: Many GO terms are significantly enriched, particularly in the tumor_vs_others comparisons, often with larger and darker red dots compared to adjacent_normal_vs_others. This suggests pronounced transcriptional changes and activated biological processes in cells within the tumor microenvironment.
- Immune Cell Activation: Immune cell types (ILC, T cell CD4+, T cell CD8+) show strong and broad enrichment for immune-related pathways in the tumor_vs_others condition. Key pathways include "Allograft rejection," "Antigen processing and presentation," "IL-17 signaling pathway," "Inflammatory bowel disease," "Th1 and Th2 cell differentiation," and "Th17 cell differentiation." These are consistently among the most highly significant enrichments.
- Metabolic and Stress Responses in Non-Immune Cells: Kidney-resident cell types (Collecting Duct Principal cell, Endothelial cell, Podocyte, Smooth muscle cell) in the tumor_vs_others condition frequently show enrichment for pathways such as "Pathways in cancer," "Oxidative phosphorylation," "PI3K-Akt signaling pathway," "Protein processing in endoplasmic reticulum," and "Ribosome." This points to altered metabolism, increased protein synthesis, and cellular stress responses.
Kidney-Specific Pathways
- Podocytes: "Diabetic cardiomyopathy" is notably and highly enriched in Podocytes in both adjacent_normal_vs_others and tumor_vs_others conditions, suggesting a predisposition or ongoing stress related to metabolic kidney disease.
- Collecting Duct Principal Cells: "Collecting duct acid secretion" is highly enriched in tumor_vs_others Collecting Duct Principal cells, indicating a specific functional alteration in these cells within the tumor context.
- Smooth Muscle Cells: "Cardiac muscle contraction" is highly enriched in Smooth muscle cells in both conditions, which is consistent with their known function and potentially altered contractility or matrix remodeling in the tumor.
Biological Interpretation
The observed pathway enrichments provide insights into the cellular states and interactions within the kidney tumor microenvironment.
- Robust Immune Activation and Inflammation:
- The consistent and highly significant enrichment of "Allograft rejection," "Antigen processing and presentation," "IL-17 signaling pathway," and T-cell differentiation pathways (Th1/Th2, Th17) in ILCs, CD4+ T cells, and CD8+ T cells within the tumor indicates a highly active immune response. This reflects the host's attempt to recognize and eliminate tumor cells, often involving sophisticated antigen presentation and diverse T-cell effector functions [1].
- The "IL-17 signaling pathway" enrichment, particularly in T cells, suggests a pro-inflammatory environment, which can have dual roles in cancer—either promoting anti-tumor immunity or fostering tumor growth and angiogenesis depending on the specific context [2].
- Enrichment of infection-related pathways (e.g., "Salmonella infection", "Tuberculosis") may reflect common immune defense mechanisms activated broadly in response to pathological stimuli, not necessarily active infection in the kidney tumor.
- Metabolic Reprogramming and Cellular Stress in Tumor-Associated Non-Immune Cells:
- The consistent upregulation of "Oxidative phosphorylation," "PI3K-Akt signaling pathway," "Pathways in cancer," "Protein processing in endoplasmic reticulum," and "Ribosome" in tumor-associated Collecting Duct Principal cells, Endothelial cells, Podocytes, and Smooth muscle cells highlights hallmarks of cancer. Tumor cells and their associated stromal cells often undergo metabolic reprogramming (e.g., increased oxidative phosphorylation or glycolysis to support rapid proliferation), heightened protein synthesis to meet growth demands, and experience endoplasmic reticulum stress due to increased protein folding [3].
- The "Tight junction" enrichment suggests altered cell-cell adhesion, which can be critical for tumor invasion and metastasis, or reflect epithelial-mesenchymal transition (EMT)-like processes in the tumor microenvironment.
- Kidney-Specific Dysfunction and Adaptation:
- The prominent enrichment of "Diabetic cardiomyopathy" in Podocytes from both adjacent normal and tumor tissues is a significant finding. Podocytes are terminally differentiated cells critical for glomerular filtration, and their dysfunction is central to diabetic nephropathy [4]. This enrichment suggests that either the patient cohort has a high incidence of diabetes or pre-existing metabolic stress impacting kidney health, which could influence tumor progression or recurrence.
- "Collecting duct acid secretion" in tumor Collecting Duct Principal cells implies an adaptive or dysregulated pH homeostasis mechanism within the tumor microenvironment. Altered pH is a known feature of many tumors and can influence drug efficacy and tumor invasiveness.
- "Cardiac muscle contraction" in smooth muscle cells points to potential alterations in vascular tone or tissue stiffness within the kidney tumor microenvironment, which can contribute to disease progression.
Clinical or Translational Implications
These findings have several potential clinical and translational implications for kidney cancer:
- Immunotherapy Targets: The robust activation of immune pathways, particularly T-cell differentiation and IL-17 signaling, suggests that immunotherapies targeting specific immune checkpoints or inflammatory pathways could be effective in a subset of kidney cancer patients. Further characterization of the immune cell states (e.g., exhausted vs. active effector T cells) would be crucial.
- Metabolic Intervention: The pervasive metabolic reprogramming observed in tumor-associated resident cells indicates potential for targeting key metabolic pathways like oxidative phosphorylation or components of the PI3K-Akt pathway as adjunct therapies to inhibit tumor growth and survival.
- Patient Stratification and Prognosis: The enrichment of "Diabetic cardiomyopathy" in podocytes could indicate a subset of patients with underlying metabolic kidney disease. Such patients might require tailored therapeutic approaches or closer monitoring for treatment side effects and overall kidney function. This also suggests the importance of considering comorbidities when managing kidney cancer.
- Biomarker Discovery: Pathways like "Collecting duct acid secretion" in Collecting Duct Principal cells or specific immune signatures could serve as biomarkers for disease progression, response to therapy, or patient stratification.
References
- Antigen processing and presentation: PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=antigen+processing+presentation+cancer+immunity
- IL-17 signaling in cancer: PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=IL-17+signaling+cancer+kidney
- Metabolic reprogramming in cancer: PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=cancer+metabolic+reprogramming+kidney
- Diabetic nephropathy and podocytes: PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=podocyte+dysfunction+diabetic+nephropathy
19. Gene Set Enrichment Analysis (GSEA) of Kidney Tumor Microenvironment Cell Types
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the differential enrichment of various biological pathways and gene sets across selected kidney cell types in the context of tumor versus adjacent normal tissue. Specifically, Gene Set Enrichment Analysis (GSEA) was performed for Collecting Duct Principal cells, Endothelial cells, ILCs, Podocytes, Smooth muscle cells, CD4+ T cells, and CD8+ T cells. Each cell type's gene expression profile in the "tumor" condition was compared against "others" (all other conditions/cells), and similarly, the "adjacent_normal" condition was compared against "others". The results are visualized as a dot plot, where the Normalized Enrichment Score (NES) indicates the direction and strength of pathway regulation (red for positive enrichment, blue for negative enrichment), and the dot size reflects the statistical significance (-log(p-val)).
Visual Summary
The dot plot displays a comprehensive overview of 80 top-enriched gene sets across the specified cell types and comparison conditions.
- Metabolic Reprogramming: Several metabolic pathways, including "Oxidative phosphorylation", "Pentose phosphate pathway", "Pyruvate metabolism", "Glutathione metabolism", "Glycolysis", and "HIF-1 signaling pathway", show distinct enrichment patterns. Notably, these pathways are frequently positively enriched (red, large dots) in Collecting Duct Principal cells, Endothelial cells, and Podocytes within the "tumor_vs_others" comparison, indicating increased activity. Conversely, they are often negatively enriched (blue) in the "adjacent_normal_vs_others" context for these same cell types.
- Proliferation and Cell Cycle: The "Cell cycle" pathway is strongly positively enriched in Collecting Duct Principal cells and Podocytes in the "tumor_vs_others" condition, suggesting active proliferation in these cell types within the tumor.
- Immune Cell Dysregulation: In ILCs, CD4+ T cells, and CD8+ T cells, "Th1 and Th2 cell differentiation" and "Th17 cell differentiation" pathways are predominantly negatively enriched (blue, large dots) in the "tumor_vs_others" comparison. Conversely, these pathways are often positively enriched in the "adjacent_normal_vs_others" comparisons for these immune cell types. The "Viral carcinogenesis" pathway shows positive enrichment in immune cells within the tumor context.
- Tissue-Specific Functions: Pathways related to normal kidney function, such as "Collecting duct acid secretion" and "Proximal tubule bicarbonate reclamation", are highly and specifically positively enriched in Collecting Duct Principal cells in the "adjacent_normal_vs_others" condition.
- Cell Adhesion and Structure: "Adherens junction" is generally negatively enriched in Podocytes and Smooth muscle cells within the "tumor_vs_others" comparison, while showing positive enrichment in the "adjacent_normal_vs_others" context for these cells.
- Conserved Tumor-Associated Pathways: Pathways like "Central carbon metabolism in cancer" and "Proteoglycans in cancer" show positive enrichment in multiple tumor cell types.
Biological Interpretation
The GSEA results highlight significant shifts in cellular processes within the kidney tumor microenvironment compared to adjacent normal tissue.
- Tumor Cell Metabolic Reprogramming: The strong positive enrichment of "Oxidative phosphorylation", "Pentose phosphate pathway", "Pyruvate metabolism", and "HIF-1 signaling pathway" in tumor-associated Collecting Duct Principal cells, Endothelial cells, and Podocytes indicates a robust metabolic reprogramming. This suggests an altered energy metabolism, often seen in cancer cells to support rapid proliferation and adaptation to the hypoxic tumor microenvironment, where HIF-1 (Hypoxia-Inducible Factor 1) plays a crucial role. This metabolic shift is a hallmark of cancer progression PubMed Search: Cancer metabolism reprogramming review.
- Increased Proliferation in Renal Epithelial Cells: The upregulation of "Cell cycle" pathways in Collecting Duct Principal cells and Podocytes in the tumor context points towards uncontrolled proliferation, a fundamental characteristic of malignancy. This suggests that non-neoplastic renal cells adjacent to tumor cells might also exhibit proliferative changes due to the tumor microenvironment.
- Immune Evasion and Dysregulation: The consistent negative enrichment of Th1, Th2, and Th17 cell differentiation pathways in ILCs, CD4+ T cells, and CD8+ T cells within the tumor suggests a state of immune suppression or exhaustion. Th1 and Th17 responses are critical for anti-tumor immunity, and their downregulation could contribute to tumor immune evasion PubMed Search: T cell exhaustion cancer. The positive enrichment of "Viral carcinogenesis" pathways in tumor-associated immune cells may reflect chronic immune activation, perhaps by tumor antigens or actual viral presence, which can also contribute to immune dysfunction or tumor promotion.
- Disruption of Tissue Architecture: The negative enrichment of "Adherens junction" in tumor-associated Podocytes and Smooth muscle cells implies a loss of cell-cell adhesion and tissue integrity. This is often associated with epithelial-mesenchymal transition (EMT) and increased invasiveness in cancer GeneCards: CDH1.
- Endothelial Cell Responses to Hypoxia: The strong positive enrichment of "HIF-1 signaling pathway" in Endothelial cells within the tumor microenvironment is consistent with their role in angiogenesis under hypoxic conditions, a critical process for tumor growth and metastasis GeneCards: HIF1A.
- Preservation of Normal Function in Adjacent Tissue: The specific enrichment of "Collecting duct acid secretion" in adjacent normal Collecting Duct Principal cells confirms that these cells retain their physiological functions, serving as a vital internal control for the analysis.
Clinical or Translational Implications
These findings provide valuable insights into the biological processes underpinning kidney cancer progression and the host response.
- Therapeutic Targets: Pathways involved in metabolic reprogramming (e.g., oxidative phosphorylation, pentose phosphate pathway, HIF-1 signaling) in tumor-associated renal cells represent potential therapeutic targets. Inhibiting these pathways could starve tumor cells or reduce their adaptability to the hypoxic environment.
- Immunotherapy Strategies: The observed suppression of Th1, Th2, and Th17 differentiation in tumor-infiltrating T cells and ILCs highlights a key mechanism of immune evasion. Strategies aimed at reversing T cell exhaustion or boosting these specific immune responses could enhance the efficacy of immunotherapies in kidney cancer patients.
- Biomarkers of Progression: The specific pathway enrichments in different cell types could serve as biomarkers for disease progression or response to therapy. For example, changes in the expression of genes within "Cell cycle" or "Adherens junction" pathways in renal epithelial cells could indicate aggressive tumor behavior.
- Understanding Tumor Microenvironment: Deciphering the cell-type-specific metabolic and immune shifts contributes to a more comprehensive understanding of the kidney tumor microenvironment, which is crucial for developing combination therapies that target both tumor cells and their supportive stromal and immune components.
20. Discussion
The comprehensive single-cell analysis of kidney tissue reveals a dramatically reconfigured cellular and molecular landscape in kidney cancer compared to adjacent normal tissue. UMAP visualizations underscore a clear segregation of tumor and normal cells, driven by both transcriptional differences and copy number variations (CNVs).
A critical finding is the genomic evidence supporting B cells as the tumor-origin cell type, an unusual primary malignancy for kidney tissue but explicitly stated in the data context, suggesting a B-cell neoplasm within the kidney. Recurrent CNV patterns, including amplifications on chromosomes 1, 2, 3, 7, 8, 11, 16, 17 and deletions on chromosomes 6, 13, 14, 18, are observed across B cells and unassigned cells in tumor samples (Section 3). Furthermore, patient-specific aneuploidy (labeled 'Unclear' ploidy), particularly prominent in sample T2, solidifies the neoplastic nature of these B cells (Section 10). These malignant B cells maintain expression of classic B-cell surface markers such as CD19, MS4A1 (CD20), CD79A, CD79B, PAX5, and CD22 (Section 15).
The tumor microenvironment (TME) undergoes extensive remodeling. Population analysis demonstrates a drastic loss of kidney-specific epithelial cells (Podocytes, Proximal Tubule, Distal Tubule, Collecting Duct Principal cells) in tumors, coupled with massive immune and stromal cell infiltration (Section 5). Within the immune compartment, while there is a significant increase in the proportion of Cytotoxic T cells (T_Cyto) in tumors (Section 8), a nuanced picture emerges from gene set enrichment analysis (GSEA). GSEA shows a *negative enrichment* of Th1, Th2, and Th17 cell differentiation pathways in tumor-infiltrating T cells and ILCs (Section 20), potentially indicating immune exhaustion or a shift towards less effective anti-tumor responses despite high cell numbers. CD4+ T cells in tumors also upregulate MHC Class II molecules (HLA-DPB1, HLA-DRA, HLA-DPA1, HLA-DRB1) and TNFRSF1B (TNFR2), suggesting chronic activation or a specific regulatory state (Section 17).
Macrophages exhibit a distinct polarization shift, with a significant *decrease* in M2A macrophages and a significant *increase* in M2B macrophages within the tumor (Section 9). M2B macrophages are known for their complex roles in inflammation and immune regulation, which in the TME, can contribute to immunosuppression and tumor progression. Tumor endothelial cells also display a pro-angiogenic phenotype with high expression of markers like ESM1, ANGPT2, and MCAM (Section 2), while fibroblasts show extensive expression of collagens and LUM, indicating their role as cancer-associated fibroblasts in extracellular matrix (ECM) remodeling (Section 16).
Cell-cell interaction (CCI) analysis highlights a dramatically increased and altered communication network in the tumor compared to normal tissue (Section 12). Key pro-tumorigenic interactions include extensive VEGF-FLT/KDR, ANGPT-TEK, and PGF-FLT1 signaling driving pathological angiogenesis (Sections 12, 14). Immune modulatory interactions like CD47-SIRPA are also noted (Section 12). Crucially, targeted CCI analysis reveals robust TGFB1-TGFBR3 and TGFB1-TGFbeta_receptor1 signaling, predominantly involving macrophages and endothelial cells in the tumor (Section 13), pointing to a central immunosuppressive and pro-fibrotic pathway. Integrin-mediated interactions related to ECM remodeling are also highly active in the TME (Sections 12, 14).
Notably, non-malignant kidney epithelial cells in the TME are also affected. Collecting Duct Principal cells exhibit a significant downregulation of several cell cycle regulatory genes (ANAPC11, ANAPC13, GADD45B, RBX1, SKP1, YWHAE, YWHAQ) (Section 18), suggesting a tumor-induced quiescent or stressed state. This contrasts with a broader GSEA finding of 'Cell cycle' pathway enrichment in tumor-associated Collecting Duct Principal cells and Podocytes (Section 20), possibly indicating complex and context-dependent cell cycle dynamics or stress responses. Furthermore, Podocytes show enrichment for 'Diabetic cardiomyopathy' pathways (Section 19), hinting at pre-existing metabolic stress or comorbidity in the patient cohort.
In summary, this study delineates the single-cell hallmarks of kidney cancer with a B-cell origin, illustrating a highly dynamic TME characterized by genomic instability, extensive immune and stromal remodeling, pathological angiogenesis, and dominant immunosuppressive signaling pathways, all contributing to a permissive environment for tumor growth.
Hypotheses:
- The specific copy number variations identified in tumor-origin B cells drive their malignant transformation and contribute to the unique pathogenesis of kidney cancer of B-cell origin.
- The altered immune landscape in the tumor microenvironment, characterized by an increase in M2B macrophages and suppression of Th1/Th2/Th17 differentiation, promotes immune evasion despite the presence of high numbers of Cytotoxic T cells.
- Enhanced TGF-beta signaling within the kidney tumor microenvironment, particularly between macrophages and endothelial cells, acts as a central mediator of immunosuppression, pathological angiogenesis, and ECM remodeling, thereby fostering tumor progression.
- The tumor microenvironment actively induces metabolic reprogramming and alters cell cycle regulation in adjacent non-malignant kidney epithelial cells, contributing to kidney dysfunction and a pro-tumorigenic niche.
Potential therapeutic targets:
- CD20 (MS4A1): CD20 is a canonical pan-B cell marker highly expressed on tumor-origin B cells, making it an excellent target for direct antibody-mediated therapy or antibody-drug conjugates in B-cell malignancies. Evidence: MS4A1 is highly expressed across 'B cell (Follicular)', 'B cell (Breg)', and 'B cell (MZ)' subsets, identified as tumor-origin cells (Section 15). Validation: Test the efficacy of anti-CD20 monoclonal antibodies (e.g., Rituximab) or next-generation CD20-targeting agents in patient-derived kidney B-cell tumor cell lines or xenograft models. Assess tumor growth inhibition and B-cell depletion.
- CD19: CD19 is another widely expressed B cell surface protein, crucial for B cell development and activation, and a proven target for immunotherapy in B-cell lymphoid malignancies, including CAR-T cell therapy. Evidence: CD19 is highly expressed on 'B cell (Follicular)', 'B cell (Breg)', and 'B cell (MZ)' subsets in the kidney (Section 15). Validation: Evaluate the anti-tumor activity of anti-CD19 antibody-drug conjugates or CAR-T cells targeting CD19 using in vitro models of kidney B-cell neoplasia and in vivo disease models.
- TGF-beta pathway (TGFB1-TGFBR3/receptor1): TGF-beta signaling is robustly upregulated in the kidney tumor microenvironment, particularly involving macrophages and endothelial cells, contributing to immunosuppression, fibrosis, and angiogenesis critical for tumor progression. Evidence: High significance and strong interactions of 'TGFB1_TGFBR3' and 'TGFB1_TGFbeta_receptor1' are observed between 'Mac|Mac', 'Mac|Endo', and 'Endo|Mac' cell pairs in tumor tissue (Section 13). Validation: Administer small molecule inhibitors of TGF-beta receptor 1 (e.g., galunisertib) or anti-TGF-beta antibodies in kidney cancer models. Monitor effects on tumor growth, metastatic spread, TME composition (macrophage polarization), and angiogenesis.
- Angiogenic pathways (VEGF-FLT1/KDR, PGF-FLT1): Pathological angiogenesis is a hallmark of tumor growth, and VEGF/PGF-FLT1/KDR interactions are key drivers of new blood vessel formation in the kidney tumor microenvironment. Tumor endothelial cells also show pro-angiogenic markers. Evidence: Strong 'VEGFA-FLT1', 'VEGFA-KDR', and 'PGF-FLT1' interactions are prominent in tumor conditions, particularly involving endothelial and smooth muscle cells (Sections 12, 14). Tumor-associated endothelial cells upregulate 'ESM1', 'ANGPT2', and 'MCAM' (Section 2). Validation: Test the efficacy of existing anti-VEGF/VEGFR drugs (e.g., bevacizumab, sunitinib, axitinib) or novel PGF/ANGPT2 inhibitors in kidney cancer models. Assess impact on tumor vascularity, growth, and survival.
- M2B Macrophages: The significant increase of M2B macrophages in kidney tumors suggests their pro-tumorigenic role in promoting immune evasion and progression. Modulating their phenotype or depleting them could enhance anti-tumor immunity. Evidence: The proportion of 'Macrophage (M2B)' is significantly higher in tumor tissue compared to adjacent normal tissue (Section 9). Macrophages are extensively involved in tumor CCI, including TGF-beta signaling (Section 12, 13). Validation: Develop and test strategies to repolarize M2B macrophages towards an M1-like anti-tumor phenotype, or to inhibit their recruitment and survival, using specific small molecules or antibodies in kidney cancer models. Evaluate changes in tumor growth and immune responses.
Follow-up validation ideas:
- Confirm the specific B-cell CNV patterns (e.g., chr6 deletion, chr8 amplification) identified in tumor samples using fluorescence in situ hybridization (FISH) or targeted sequencing on sorted B cells from fresh patient kidney tumor biopsies.
- Perform multiplex immunofluorescence or spatial transcriptomics on kidney tumor sections to map the precise localization and protein expression of M2A/M2B macrophage markers, Cytotoxic T cell activation/exhaustion markers (e.g., PD-1, CD27, TNFRSF1B), and key CCI ligand-receptor pairs (e.g., TGFB1-TGFBR3, PGF-FLT1, CD47-SIRPA) within the tumor microenvironment.
- Conduct in vitro perturbation assays using patient-derived B-cell tumor organoids or cell lines to assess the functional impact of targeting identified surface markers (CD19, CD20) and key pathways (TGF-beta, VEGF/PGF signaling) on proliferation, survival, and interaction with immune cells.
- Investigate the functional consequences of altered macrophage polarization by isolating M2B macrophages from kidney tumors and testing their ability to suppress T cell activity or promote angiogenesis in co-culture systems, and evaluate the effect of repolarizing agents.
- Utilize an orthotopic mouse model of B-cell kidney neoplasia (if available or generated) to evaluate the therapeutic efficacy of targeting TGF-beta, VEGF/PGF, or B-cell specific surface antigens on tumor growth, metastasis, and the remodeling of the kidney TME.
- Analyze additional patient cohorts (validation cohorts) using bulk RNA-seq or targeted gene expression panels to validate the prognostic or predictive value of identified gene expression signatures (e.g., T-cell differentiation pathways, cell cycle regulators in epithelial cells) or cell type proportions in kidney cancer.
Limitations:
This single-cell RNA-seq analysis provides a snapshot of the cellular and molecular landscape, and observed associations do not imply causation without further functional validation. The inference of CNVs from RNA-seq data, while informative, has inherent limitations, and 'Unclear' ploidy calls warrant orthogonal genomic validation. The explicit designation of 'B cell' as the tumor-origin cell type in kidney tissue, though unusual for primary renal malignancies, is based on the provided data context and requires careful consideration in a broader clinical context. Patient-to-patient heterogeneity in tumor biology, especially regarding genomic instability and immune responses, is observed, emphasizing the need for larger cohorts to generalize findings. Finally, the functional status of immune cells, particularly the potential exhaustion of T cells despite high infiltration, requires deeper investigation beyond expression and proportion metrics.
21. Query List
- Show and save UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns.
- Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
- Show and save CNV heatmap for B cell (tumor-origin cells) and unassigned cells, grouped by sample. Include a summary of significantly amplified copy number regions.
- Show and save CNV patterns on UMAPs, including major cell type, minor cell type, ploidy results, condition, and sample in 2 columns.
- Show and save population bar plot for minor cell types.
- Show and save subset population barplot for T cells.
- Show and save subset population barplot for Macrophages.
- Show and save boxplots for statistically significant differences in T cell subset populations between conditions. Determine ncols appropriately based on the total number of panels.
- Show and save boxplots for statistically significant differences in Macrophage subset populations between conditions. Determine ncols appropriately based on the total number of panels.
- Show and save ploidy population barplot for B cell (tumor-origin cells) and unassigned cells.
- Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
- Show and save cell-cell interactions for genes related to immune checkpoint and cell cycle pathways.
- Find and save dot plots for statistically significant differences in cell-cell interactions between conditions for major immune and stromal cells. Set max_n_items_per_group = 25.
- Show the condition-specific markers for tumor-origin cells (B cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
- Extract and save dot plot for condition-specific markers of Fibroblasts. Show up to 50 surfaceome markers per condition.
- Extract and save dot plot for condition-specific markers of CD4 T cells. Show up to 50 surfaceome markers per condition.
- Show and save boxplots for statistically significant differences in expression of Cell cycle pathway-related genes between conditions for Collecting Duct Principal cell, Endothelial cell, ILC, Podocyte, Smooth muscle cell, T cell CD4+, T cell CD8+. Set max_n_items_to_plot = 24 and ncols to achieve an aspect ratio of approximately 2x3.
- Show and save bar-plots of Gene ontology (GSA) analysis results for Collecting Duct Principal cell, Endothelial cell, ILC, Podocyte, Smooth muscle cell, T cell CD4+, T cell CD8+.
- Show and save dot plot of Gene set enrichment analysis results for Collecting Duct Principal cell, Endothelial cell, ILC, Podocyte, Smooth muscle cell, T cell CD4+, T cell CD8+. Use RdBu_r as color map and set n_pws_to_show = 80.


















